{"gene":"C5","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1969,"finding":"A neutrophil chemotactic factor was identified as a fragment derived from complement component C5 (C'5), establishing that C5 cleavage generates a potent leukocyte chemoattractant (C5a).","method":"In vitro chemotaxis assay with C5-derived fractions","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — foundational functional characterization, replicated widely across subsequent decades","pmids":["5765461"],"is_preprint":false},{"year":1978,"finding":"Complete primary structure of human C5a was determined: 74 amino acids with a single complex oligosaccharide at Asn64, three disulfide bonds, and a C-terminal Arg74 critical for chemotactic activity (removal as C5a-desArg reduces leukotaxis).","method":"Protein sequencing, carbohydrate analysis, functional chemotaxis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct protein sequencing with functional validation, foundational structure-function study","pmids":["690134"],"is_preprint":false},{"year":1978,"finding":"C3a and C5a were shown to be chemotactic for human leukocytes in vitro; C5a is substantially more potent than C3a as a leukocyte chemoattractant.","method":"In vitro leukotaxis assays; in vivo stimulated conditions","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1/2 — replicated foundational functional assay across multiple conditions","pmids":["342601"],"is_preprint":false},{"year":1983,"finding":"Limited cleavage of the C5 alpha-chain by non-complement proteases (trypsin, thrombin, plasmin, elastase) generates C5a-like biological activities (neutrophil enzyme release and chemotaxis) without releasing free polypeptide fragments; the cleaved fragments remain disulfide-bonded to the C5 molecule.","method":"In vitro proteolysis, SDS-PAGE, gel filtration, neutrophil functional assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with multiple enzymes and orthogonal structural/functional readouts","pmids":["6222137"],"is_preprint":false},{"year":1985,"finding":"The C5a receptor on human PMN was identified by affinity cross-linking with 125I-C5a; the receptor binding moiety has an apparent molecular mass of ~40 kDa (complex ~52 kDa), distinct from nonspecific proteins, and shows specificity for C5a over fMLP and LTB4.","method":"Affinity cross-linking with disuccinimidyl suberate, SDS-PAGE, competition binding","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct affinity labeling with rigorous specificity controls","pmids":["3997862"],"is_preprint":false},{"year":1985,"finding":"A three-dimensional model of C5a was built by comparative modeling from the C3a crystal structure, predicting conservation of the 4-helix core while external residues differ; the model suggested a possible receptor-binding site on C5a.","method":"Comparative molecular modeling based on C3a crystal structure","journal":"Science","confidence":"Low","confidence_rationale":"Tier 4 — computational modeling only, no experimental validation in this paper","pmids":["3992245"],"is_preprint":false},{"year":1986,"finding":"C5b-6 requires negatively charged phospholipids (phosphatidylglycerol or phosphatidic acid) for initial membrane binding; after forming C5b-7, the complex inserts into membranes of all phospholipid compositions with ~20-fold selectivity for small over large unilamellar vesicles. C6 and C7 associate preferentially with the alpha'-chain of C5b.","method":"Lipid vesicle binding assays, activation energy measurements, bimolecular kinetics","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted membrane insertion with defined lipid compositions and kinetic characterization","pmids":["3801440"],"is_preprint":false},{"year":1988,"finding":"C5a des-Arg (lacking C-terminal Arg74) retains in vivo inflammatory activity in human skin (wheal-and-flare, neutrophil infiltration, mast cell degranulation) but is less potent than intact C5a, indicating the C-terminal arginine enhances but is not absolutely required for all biological activities.","method":"Intradermal injection in human volunteers, histological analysis, in vitro binding","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — direct human in vivo challenge with purified proteins, histological confirmation","pmids":["3351304"],"is_preprint":false},{"year":1989,"finding":"C5a receptors on human eosinophils display two populations (high-affinity Kd ~31 pM, ~17,500 sites/cell; low-affinity Kd ~100 nM), with a C5a-receptor cross-linked complex of ~60-65 kDa — larger than the neutrophil receptor complex (~52 kDa) — suggesting distinct receptor molecules on eosinophils versus neutrophils.","method":"125I-C5a binding (Scatchard analysis), covalent cross-linking with DSS, SDS-PAGE, cyanogen bromide cleavage","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — rigorous receptor pharmacology with direct affinity labeling and structural comparison","pmids":["2912983"],"is_preprint":false},{"year":1989,"finding":"Three-dimensional NMR spectroscopy (3D heteronuclear 1H-15N) of uniformly 15N-labeled C5a was demonstrated, providing resonance assignments and distance constraints consistent with a 4-helix bundle core structure and a flexible C-terminus.","method":"3D heteronuclear NMR spectroscopy with 15N-labeled recombinant C5a","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct NMR structural characterization with isotope labeling","pmids":["2730871"],"is_preprint":false},{"year":1991,"finding":"The human C5a receptor was cloned from U937 and HL-60 cells; expression in COS-7 cells confirmed high-affinity C5a binding. The deduced amino acid sequence revealed seven hydrophobic transmembrane domains, placing C5aR in the G-protein-coupled receptor superfamily.","method":"cDNA cloning, heterologous expression in COS-7 cells, radioligand binding","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1/2 — direct cloning with functional reconstitution, replicated in multiple cell types","pmids":["1847994"],"is_preprint":false},{"year":1992,"finding":"The structure of complement C5b-7 was elucidated: plasmin cleaves C5b's alpha'-chain into C5c (Mr 142,000) and C5d (Mr 43,000); antibodies to C5c block C5b-6 interaction with C7, while antibodies to C5d inhibit C5 binding to C3b; chemical cross-linking showed both C6 and C7 associate preferentially with the alpha'-chain of C5b, and the C-terminal cysteine-rich domains of C6 and C7 bind specifically to C5.","method":"Limited proteolysis, circular dichroism, polyclonal antibody blocking, chemical cross-linking, solid-phase binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal structural and functional methods, defined binding domains","pmids":["1387399"],"is_preprint":false},{"year":1993,"finding":"Terminal complement complexes C5b-7, C5b-8, and C5b-9 (MAC) generate non-lethal cellular signals including Ca2+ influx and second messengers (cAMP, inositol phosphates, arachidonate metabolites) in a cell-type-specific manner, demonstrating signaling functions of the MAC beyond cytolysis.","method":"Cell signaling assays, ion flux measurements, second messenger quantification in specific cell types","journal":"Immunologic research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple signaling readouts but review-style compilation without single definitive structural experiment","pmids":["8288945"],"is_preprint":false},{"year":1994,"finding":"C5a receptor activation in human neutrophils signals through Gi proteins to activate both B-Raf and Raf-1 (with temporally distinct kinetics), MEK-1, and MAP kinase, as well as Ras (via guanine nucleotide exchange); both PKC-dependent and -independent pathways contribute, and PKA activation inhibits Raf.","method":"Kinase activity assays, Ras GTP-loading assay, pertussis toxin (Gi inhibition), PKC modulators, cAMP/PKA manipulation in human neutrophils","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal signaling pathway assays with pharmacological dissection","pmids":["8090790"],"is_preprint":false},{"year":1994,"finding":"Site-directed mutagenesis of recombinant human C5a identified 10 non-contiguous charged amino acids in the 4-helix core plus the C-terminal Arg74 as comprising the pharmacophore; Arg74 substitution produced the largest single reduction in receptor binding and Ca2+ mobilization; C3a/C5a hybrid analysis confirmed the two-domain pharmacophore model.","method":"Site-directed mutagenesis, receptor binding assay, intracellular Ca2+ mobilization assay","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with multiple functional readouts across the full protein","pmids":["7987211"],"is_preprint":false},{"year":1994,"finding":"Mutagenesis of human C5a confirmed that Lys19 and/or Lys20 are critical receptor-interacting residues (>30-fold activity loss on double replacement), while Arg40 and Pro45 replacements had little effect; des-Arg74 C5a retains C5aR activation in Xenopus oocytes but is inactive in the guinea pig ileum assay, revealing species-specific receptor differences.","method":"Site-directed mutagenesis, myeloperoxidase-release assay from granulocytes, Xenopus oocyte expression, CD spectroscopy for structural integrity","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — site-directed mutagenesis with structural and functional validation across multiple assay systems","pmids":["8112341"],"is_preprint":false},{"year":1994,"finding":"C5a receptors on C5aR-deficient mice revealed that the C5a receptor is required for non-redundant mucosal host defence; C5aR knockout mice failed to clear Pseudomonas aeruginosa despite increased neutrophil influx, indicating C5aR controls neutrophil effector function rather than merely recruitment.","method":"C5aR gene disruption (knockout mice), intrapulmonary bacterial challenge, bacterial clearance assays, neutrophil quantification","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with specific in vivo phenotypic readout","pmids":["8779720"],"is_preprint":false},{"year":1995,"finding":"Agonist-occupied C5aR is phosphorylated by a G protein-coupled receptor kinase independently of Gi activation (pertussis toxin-insensitive); receptor dephosphorylation by PP1/PP2A-type phosphatases (okadaic acid-sensitive) is required for recycling of internalized C5aR back to the plasma membrane, suggesting dephosphorylation enables receptor resensitization.","method":"32P-phosphorylation assays, pertussis toxin treatment, okadaic acid (phosphatase inhibitor), receptor internalization/recycling kinetics in differentiated HL60 cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1/2 — mechanistic dissection of receptor phosphorylation/dephosphorylation cycle with pharmacological tools","pmids":["7706744"],"is_preprint":false},{"year":1997,"finding":"C3a and C5a are chemotactic factors for human mast cells (HMC-1 line, cord blood-derived mast cells, cutaneous mast cells); migration requires extracellular matrix (laminin), is dose-dependent, inhibited by specific antibodies, and blocked by pertussis toxin indicating Gi protein coupling; both anaphylatoxins also mobilize intracellular Ca2+ in mast cells.","method":"Chemotaxis assays on laminin matrix, pertussis toxin treatment, calcium imaging with Fura-2","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including signaling readouts and pharmacological inhibition across multiple human mast cell types","pmids":["9108406"],"is_preprint":false},{"year":2000,"finding":"In renal ischemia/reperfusion injury, C5-deficient and C6-deficient (but not C4-deficient) mice are protected, and C6-deficient mice treated with anti-C5a showed no additional protection; reconstitution of C6 alone restored injury in C6-deficient mice. This demonstrates that the membrane attack complex (C5b-9, requiring both C5 and C6) rather than C5a-mediated neutrophil infiltration is the predominant mediator of renal I/R injury.","method":"Complement-deficient mouse models, renal artery occlusion model, histology, functional assays, antibody neutralization, reconstitution experiments","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with reconstitution experiment across multiple complement-deficient strains","pmids":["10811844"],"is_preprint":false},{"year":2001,"finding":"Sublytic C5b-9 (MAC) activates the cell cycle and promotes cell survival via Gi-mediated ERK1/2 activation and PI3K/Akt pathway, which inhibits apoptosis through regulation of BAD; C5b-9 also reverses differentiated phenotype of postmitotic cells such as oligodendrocytes.","method":"Cell cycle analysis, kinase activity assays (ERK, PI3K/Akt), apoptosis assays, differentiation markers","journal":"Immunological reviews","confidence":"Medium","confidence_rationale":"Tier 2 — multiple signaling readouts but review compilation of prior work","pmids":["11414362"],"is_preprint":false},{"year":2001,"finding":"Tyrosines at positions 11 and 14 of the C5aR N-terminal domain are post-translationally sulfated; these sulfate moieties are critical for C5a binding and Ca2+ mobilization. A C5aR variant lacking sulfation responds normally to a small peptide agonist but not to intact C5a, supporting a two-site model where the sulfated N-terminus mediates the initial docking interaction with C5a.","method":"Post-translational modification analysis, site-directed mutagenesis, 35S-sulfate labeling, Ca2+ mobilization assay, peptide inhibition assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — identification of specific PTM with mutagenesis, isotope labeling, and multiple functional assays supporting two-site docking model","pmids":["11342590"],"is_preprint":false},{"year":2001,"finding":"Rainbow trout C5 (first non-human/mouse C5 cloning) shows ~60% similarity to human C5, is expressed as a single gene in liver, confirming evolutionary conservation of C5 structure and hepatic expression across vertebrates.","method":"cDNA library cloning, Northern blot, Southern blot, mass spectrometry of tryptic digests, protein purification","journal":"Developmental and comparative immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct molecular cloning with protein-level validation by mass spectrometry","pmids":["11356221"],"is_preprint":false},{"year":2001,"finding":"Sublytic C5b-9 induces ERK activation in glomerular epithelial cells via Ras and, in part, PKC-dependent pathways; this ERK activation depends on actin cytoskeletal integrity (blocked by cytochalasin D and latrunculin B) and is attenuated by constitutively active RhoA and ROCK inhibition; ERK activation leads to phosphorylation of cytosolic PLA2 and MAPKAPK-2 but not Elk-1, and is functionally distinct from the cytotoxic pathway.","method":"Dominant-negative Ras, pharmacological inhibitors (cytochalasin D, latrunculin B, ROCK inhibitor), constitutively active RhoA overexpression, kinase phosphorylation assays","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 1/2 — multiple orthogonal genetic and pharmacological tools dissecting pathway components","pmids":["15855657"],"is_preprint":false},{"year":2002,"finding":"C5 convertase specificity is regulated by C3b deposition density: monomeric C3b-containing convertases have a Km for C5 of ~25 µM (poor C5 cleavage); deposition of additional C3b on cell surfaces creates C3b-C3b and C4b-C3b complexes that shift Km for C5 more than 1000-fold (below physiological C5 concentration), switching the enzyme from C3 to C5 cleavage and initiating MAC formation.","method":"In vitro enzyme kinetics (Km determination), cell surface complement activation assays, convertase assembly reconstitution","journal":"Biochemical Society transactions","confidence":"High","confidence_rationale":"Tier 1 — quantitative enzyme kinetics with reconstituted convertase showing >1000-fold Km shift","pmids":["12440962"],"is_preprint":false},{"year":2002,"finding":"Activated phagocytic cells (neutrophils and alveolar macrophages) generate biologically active C5a from exogenous C5 via a serine protease-dependent mechanism that is sensitive to transcription/translation inhibitors in macrophages but only partially in neutrophils, indicating a novel complement-independent pathway for C5a generation by phagocytes.","method":"Incubation of phagocytes with C5, antibody detection of C5a, serine protease inhibitors (aprotinin), actinomycin D/cycloheximide treatment, chemotaxis bioassay","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 1/2 — direct demonstration of cell-mediated C5 cleavage with serine protease inhibition and transcription inhibitor controls","pmids":["12414531"],"is_preprint":false},{"year":2002,"finding":"Carboxypeptidase R (thrombin-activatable fibrinolysis inhibitor, TAFI) cleaves the C-terminal Arg from C5a much more efficiently than the classical carboxypeptidase N, inactivating the anaphylatoxin; upregulation of proCPR in inflammatory states suggests CPR is a major physiological inactivator of C5a.","method":"In vitro enzyme assay with C5a octapeptide substrate, kinetic comparison of CPR versus CPN activity","journal":"Microbiology and immunology","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro enzymatic assay comparing two carboxypeptidases on C5a substrate","pmids":["11939578"],"is_preprint":false},{"year":2003,"finding":"C5L2 (GPR77/C5aR2) is a high-affinity C5a binding protein that is obligately uncoupled from heterotrimeric G proteins due to a Leu-for-Arg substitution in the DRY sequence at the end of transmembrane segment 3; it shows weak phosphorylation, no MAP kinase activation, no Ca2+ flux, and no chemotaxis induction upon C5a binding, and it does not interact with C3a or C4a.","method":"Radioligand binding, G-protein coupling assays (cAMP, calcium flux), MAP kinase assays, phosphorylation assays, chemotaxis assay, microarray analysis of C5aR-KO vs. C5L2-only cells, sequence analysis of DRY motif","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1/2 — comprehensive pharmacological and biochemical characterization with mechanistic identification of DRY motif alteration","pmids":["12899627"],"is_preprint":false},{"year":2003,"finding":"C3a and C5a anaphylatoxins are essential for liver regeneration: C3- or C5-deficient mice show high mortality and impaired regeneration after partial hepatectomy; combined deficiency is rescued by reconstitution with both C3a and C5a; C5aR signaling is required for IL-6/TNFα induction and NF-κB/STAT-3 activation in the early priming phase of hepatocyte proliferation.","method":"Complement-deficient mouse models, partial hepatectomy, cytokine ELISA, NF-κB/STAT-3 activation assays, reconstitution with recombinant C3a/C5a","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with rescue reconstitution and defined signaling pathway readouts","pmids":["12975457"],"is_preprint":false},{"year":2005,"finding":"Complement factor C5 (encoded by the Hc gene) was identified as the quantitative trait gene underlying a hepatic fibrosis susceptibility locus; small molecule C5aR antagonists had antifibrotic effects in vivo, and common C5 haplotype polymorphisms associated with advanced fibrosis in human hepatitis C, establishing C5/C5a-C5aR as a causal pathway in fibrogenesis.","method":"In silico QTL mapping, congenic mice, transgenesis with recombined artificial chromosomes (BAC/YAC), C5aR antagonist treatment, human genetic association","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1/2 — genetic causality established by transgenesis/congenic mapping with in vivo pharmacological validation","pmids":["15995705"],"is_preprint":false},{"year":2006,"finding":"C3a and C5a generated in drusen induce VEGF expression in retinal pigmented epithelium in vitro and in vivo; genetic ablation of C3aR or C5aR reduces VEGF, leukocyte recruitment, and choroidal neovascularization after laser injury, establishing C5a-C5aR signaling as a mechanistic link between complement activation and angiogenesis in AMD.","method":"VEGF ELISA from C5a/C3a-stimulated cells, C3aR/C5aR knockout mice, laser-induced CNV model, leukocyte recruitment quantification, antibody neutralization, pharmacological receptor blockade","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus antibody neutralization plus pharmacological blockade converging on same mechanistic conclusion","pmids":["16452172"],"is_preprint":false},{"year":2007,"finding":"C5L2 (GPR77) facilitates C5a signaling in neutrophils, macrophages, and fibroblasts in vitro and is required for optimal C5a-mediated inflammatory cell infiltration in vivo; C5L2-deficient mice are hypersensitive to LPS-induced septic shock, show reduced OVA-induced airway hyper-responsiveness, and are mildly delayed in hematopoietic regeneration after irradiation — phenotypes mirroring C3aR-deficient mice.","method":"Gene targeting (C5L2 KO mice), in vitro signaling assays in primary cells, in vivo LPS sepsis model, OVA airway inflammation model, gamma-irradiation hematopoiesis recovery","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with multiple orthogonal in vivo and in vitro readouts","pmids":["17322907"],"is_preprint":false},{"year":2008,"finding":"C5ar (C5aR1) and C5l2 (C5aR2/GPR77) contribute synergistically to harmful outcomes in sepsis; C5l2 specifically is required for in vivo and in vitro release of HMGB1 in a C5ar-independent manner; combined blockade of both receptors is required for protection in high-grade sepsis.","method":"Cecal ligation and puncture (CLP) model, receptor knockout mice, anti-receptor antibody blockade, HMGB1 ELISA, cytokine profiling","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — dual genetic KO and antibody blockade with specific mechanistic readout (HMGB1 release)","pmids":["18454156"],"is_preprint":false},{"year":2009,"finding":"C5a and C5a-desArg signal through C5aR on dorsal root ganglia neurons to induce Ca2+ influx and sensitize C-nociceptors to heat; C5a sensitizes heat-responsive C-fibers (lower threshold, more action potentials) and activates A-nociceptors; C5aR mRNA is expressed in DRG.","method":"In vivo intraplantar injection, in vitro skin-nerve preparation, Ca2+ imaging (Fura-2), RT-PCR for C5aR mRNA in DRG","journal":"Pain","confidence":"High","confidence_rationale":"Tier 2 — direct C-fiber electrophysiology combined with Ca2+ imaging and in vivo behavioral validation","pmids":["20031321"],"is_preprint":false},{"year":2012,"finding":"Ischemic cortical neurons constitutively express C5 (the C5a precursor) and CD88 (C5aR); glucose deprivation or OGD increases C5a levels in culture media and upregulates CD88; exogenous C5a induces neuronal apoptosis; PMX53 (CD88 antagonist) or CD88 knockout reduces ischemia-induced apoptosis ~50%; CD88-KO mice have reduced infarct volumes after MCAO, demonstrating a local autocrine/paracrine C5a-CD88 apoptotic signaling loop in neurons.","method":"Primary neuronal culture, oxygen-glucose deprivation, C5a ELISA, CD88 antagonist (PMX53), CD88-KO mice, MCAO stroke model, infarct volume measurement","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo genetic/pharmacological evidence converging on a defined apoptotic mechanism","pmids":["22651932"],"is_preprint":false},{"year":2012,"finding":"C5a promotes migration, proliferation, and 3D tube/ring formation of human microvascular endothelial cells (HMEC-1) in a dose-dependent manner via C5aR; C5aR antagonist W-54011 suppresses all these activities; Matrigel plug assay confirms pro-angiogenic effect in vivo.","method":"Cell cycle/proliferation assays (BrdU/FACS), Chemotaxicell migration assay, collagen gel ring formation, Matrigel plug in vivo, C5aR antagonist W-54011","journal":"Inflammation research","confidence":"High","confidence_rationale":"Tier 2 — multiple in vitro functional assays with receptor-specific pharmacological inhibition and in vivo confirmation","pmids":["20217457"],"is_preprint":false},{"year":2013,"finding":"C5a selectively induces migration of STRO-1+/C5aR+ pulp progenitor cells via C5aR; perivascular localization of these progenitor cells was confirmed; C5aR antagonist W54011 blocks C5a-induced progenitor migration, and C5b-9 is detected in carious teeth, suggesting complement activation generates a C5a gradient that guides stem cell recruitment for dentin regeneration.","method":"Immunofluorescence, RT-PCR on STRO-1-sorted cells, C5aR antagonist-blocked migration assays, immunohistochemistry for C5b-9","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 3 — receptor antagonist migration assay in primary cells with localization data; single lab","pmids":["23603337"],"is_preprint":false},{"year":2013,"finding":"Lung cancer cells constitutively produce C5a from C5 via a membrane-bound serine protease (sensitive to aprotinin and a furin-like inhibitor but not cysteine, acid, or metalloprotease inhibitors); this C5a acts on C5aR-expressing cancer cells to enhance invasion in vitro.","method":"C5a ELISA from conditioned media, serine protease inhibitor panel (aprotinin, RVKR-cmk), invasion assay, anti-C5a antibody neutralization","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional assay with protease inhibitor panel and neutralizing antibody, single lab","pmids":["25050844"],"is_preprint":false},{"year":2014,"finding":"A heterozygous C5 missense mutation p.Arg885His (c.2654G→A), present in ~3.2% of Japanese and Han Chinese individuals, generates functionally active C5 that causes hemolysis normally but fails to bind eculizumab; this variant accounts for poor response to eculizumab in PNH patients. A second binding antibody (N19-8) targeting a different C5 epitope blocks both wild-type and mutant C5.","method":"Gene sequencing, in vitro hemolysis assay with mutant C5, eculizumab binding assay, N19-8 antibody blocking assay","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1/2 — direct functional characterization of variant protein with antibody binding assays and hemolysis reconstitution","pmids":["24521109"],"is_preprint":false},{"year":2014,"finding":"Porphyromonas gingivalis peptidylarginine deiminase (PPAD) citrullinates the critical C-terminal Arg74 of C5a, disabling its function: citrullinated C5a shows diminished neutrophil chemotaxis and reduced Ca2+ signaling via C5aR; P. gingivalis outer membrane vesicles generate fully citrullinated C5a (Arg74Cit) while PPAD-null vesicles do not.","method":"In vitro PPAD treatment of C5a, neutrophil chemotaxis assay, Ca2+ imaging (Fura-2 AM) in U937/C5aR cells, mass spectrometry (citrullination mapping), outer membrane vesicle treatment of C5","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — direct enzymatic modification with mass spectrometric site identification and multiple functional readouts","pmids":["25324545"],"is_preprint":false},{"year":2015,"finding":"Neutrophil-derived phosphatidylserine-positive microvesicles suppress C5a-mediated priming of the NLRP3 inflammasome (reducing IL-1β release and neutrophil influx) via the PS-receptor MerTK; in a murine MSU peritonitis model, C5a generated after MSU injection primes the inflammasome, and PMN-derived ectosomes (generated in response to C5a) act as a negative-feedback autoregulatory loop requiring C5aR on resident cells.","method":"C5aR-KO mice, MerTK-KO mice, MSU peritonitis model, IL-1β ELISA, PS-liposome functional mimics, human joint aspirate ectosomes","journal":"Annals of the rheumatic diseases","confidence":"High","confidence_rationale":"Tier 2 — multiple KO mouse models with mechanistic reconstitution using PS liposomes","pmids":["26245757"],"is_preprint":false},{"year":2016,"finding":"Three crystal structures of C5 in complex with distinct tick-derived inhibitors (OmCI, a second OmCI-class inhibitor, and eculizumab Fab) reveal three non-overlapping binding sites on C5 that all prevent its activation by C5 convertases; all three complexes competitively inhibit the C5 convertase, inconsistent with simple steric blockade and suggesting a priming/conformational event is required for C5 activation.","method":"X-ray crystallography of C5-inhibitor complexes, cryo-EM, competitive inhibition assays of C5 convertase","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 — multiple crystal structures with functional convertase inhibition assays; mechanistic model supported by structural comparison","pmids":["27018802"],"is_preprint":false},{"year":2018,"finding":"Two crystal structures of human C5aR in ternary complexes reveal orthosteric action of the peptide antagonist PMX53 (stabilizing the C5aR structure) and allosteric binding of non-peptide antagonists (avacopan and NDT9513727) at a distinct intracellular allosteric site with different binding poses; helix 8 adopts a novel conformation relevant to C5aR activation.","method":"X-ray crystallography of C5aR ternary complexes, computational docking, biophysical binding assays, cell-based signaling assays","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structures with multiple orthogonal validation methods defining orthosteric and allosteric sites","pmids":["29867214"],"is_preprint":false},{"year":2019,"finding":"C5aR2 (the 'atypical' C5a receptor) expressed on endothelial cells transports C5a from tissue into the vessel lumen via a transcytosis-like mechanism (intravital microscopy); this transported C5a is required to initiate C5aR1-mediated neutrophil arrest, while ACKR1 transports chemokines for CXCR2-dependent transendothelial migration — defining distinct roles for the two transport receptors in sequential steps of neutrophil recruitment.","method":"Intravital microscopy in live mice, immune complex arthritis model, C5aR2-KO and ACKR1-KO mice, fluorescent C5a tracking","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 — intravital microscopy with genetic KO models demonstrating transcytotic transport mechanism in vivo","pmids":["31076525"],"is_preprint":false},{"year":2019,"finding":"C5aR2 physically interacts with C5aR1 and β-arrestin to negatively modulate C5aR1 signaling; in an MPO-ANCA GN model, C5aR2 deficiency worsens disease while C5aR1 deficiency ameliorates it, demonstrating that C5aR1 engagement enhances inflammation and C5aR2 engagement suppresses inflammation in the same in vivo context.","method":"C5aR2-KO, C5aR1-KO, and human C5aR knock-in mice; MPO-ANCA GN model; CCX168 (C5aR1 antagonist) oral administration; co-immunoprecipitation of C5aR2-C5aR1-β-arrestin complex","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 — genetic and pharmacological evidence with Co-IP demonstrating physical C5aR1/C5aR2/β-arrestin interaction","pmids":["24179165"],"is_preprint":false},{"year":2019,"finding":"A CirpT inhibitor from tick saliva binds directly to the peripheral MG4 domain of C5 (solved by cryo-EM at the full-C5 level and X-ray crystallography of C5_MG4-CirpT at 2.7 Å); this interaction prevents C5 activation by competitively inhibiting the C5 convertase, providing structural evidence that the MG4 domain is functionally important for convertase-mediated C5 activation.","method":"Cryo-electron microscopy (C5-CirpT complex), X-ray crystallography (C5_MG4-CirpT at 2.7 Å), direct binding assays, convertase inhibition assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM and crystal structure with functional convertase inhibition validation","pmids":["31871188"],"is_preprint":false},{"year":2021,"finding":"C5a-C5aR1 activation on platelets induces preferential release of CXCL4 (PF4), an antiangiogenic factor; platelet-specific C5aR1 deletion produces a proangiogenic phenotype with increased collateralization and capillarization; growth factor- and hypoxia-driven vascularization is markedly increased in global C5ar1-/- mice; interfering with the C5aR1-CXCL4 axis reverses the antiangiogenic platelet effect in vitro and in vivo.","method":"Platelet-specific C5aR1 KO mice, global C5ar1-/- mice, CXCL4 ELISA from C5a-stimulated platelets, endothelial cell migration/tube formation assays, in vivo angiogenesis models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — platelet-specific and global KO models with defined molecular effector (CXCL4) and in vitro/in vivo confirmation","pmids":["34099640"],"is_preprint":false},{"year":2023,"finding":"C5a-C5aR1 signaling promotes fungal clearance and host survival in systemic candidiasis by stimulating phagocyte effector function and ERK- and AKT-dependent phagocyte survival in infected tissues; C5ar1 ablation rewires macrophage metabolism downstream of mTOR, promoting macrophage apoptosis. Critically, local C5 produced intrinsically by phagocytes (not only hepatocyte-derived C5) provides a key substrate for antifungal protection.","method":"C5ar1-KO mice, Candida infection model, RNA-seq, metabolomics, mTOR pathway inhibitors, phagocyte-specific C5 expression analysis, patient cohort correlation of C5a levels with outcome","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with mechanistic dissection of ERK/AKT/mTOR pathway and identification of phagocyte-intrinsic C5 production as key substrate source","pmids":["37220746"],"is_preprint":false},{"year":1988,"finding":"Complement C5 is the molecular basis of the hepatic fibrosis susceptibility QTL (Hc locus): congenic mice and BAC transgenesis with the Hc gene confirmed that C5 underlies fibrosis susceptibility; C5aR antagonist treatment had antifibrotic effects, linking C5 cleavage to C5a-C5aR-mediated fibrogenesis.","method":"Congenic mouse mapping, BAC transgenesis, C5aR antagonist in vivo treatment, liver fibrosis quantification","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1/2 — genetic causality established by transgenesis with in vivo pharmacological validation","pmids":["15995705"],"is_preprint":false},{"year":2002,"finding":"C5a anaphylatoxin regulates the activating/inhibitory FcγR balance on alveolar macrophages: C5a upregulates FcγRIII (activating) and downregulates FcγRII (inhibitory) via C5aR signaling; this bidirectional modulation is required for efficient cytokine production and neutrophil recruitment in immune complex-induced lung disease, connecting C5a to FcγR-complement crosstalk.","method":"FcγR expression by flow cytometry on alveolar macrophages, recombinant C5a stimulation, C5aR-KO and FcγRIII-KO mice, immune complex pulmonary model, cytokine ELISA","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic KO models with in vitro and in vivo mechanistic readouts, specific receptor-pathway linkage","pmids":["12488432"],"is_preprint":false},{"year":2009,"finding":"CFHR1 (Factor H-related protein 1) inhibits complement C5 convertase activity and C5b surface deposition and MAC formation through a mechanism distinct from factor H (which inhibits C3 convertase); CFHR1 and factor H bind overlapping surface sites, suggesting sequential control of complement activation — factor H limits C3 convertase, CFHR1 limits C5 convertase/terminal pathway.","method":"C5 convertase activity assay (inhibition by CFHR1), C5b and MAC deposition assays on cell surfaces, competition binding with factor H","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1/2 — direct in vitro enzymatic inhibition assays defining a novel regulatory mechanism","pmids":["19528535"],"is_preprint":false}],"current_model":"Complement C5 is cleaved at its alpha-chain by C5 convertases (whose C5-specificity is allosterically triggered by C3b density), as well as by non-complement serine proteases from phagocytes and cancer cells, to release the 74-amino acid anaphylatoxin C5a (whose C-terminal Arg74 and core residues Lys19/20 are critical pharmacophore elements) and C5b; C5a signals primarily through the sulfated-tyrosine N-terminal docking site of C5aR1 (a Gi-coupled GPCR activating Ras/Raf/MEK/ERK and PI3K/Akt), is inactivated by carboxypeptidase R/N, and is modulated by C5aR2 which acts as a transport receptor on endothelium and a negative regulator of C5aR1 via physical interaction with β-arrestin; C5b sequentially recruits C6 (via alpha'-chain interactions), then C7 (via cysteine-rich C6/C7 domains), and inserts into membranes to form the lytic and signaling-competent MAC (C5b-9), whose sublytic form activates ERK, PI3K/Akt, and cell cycle entry; three structurally distinct inhibitor-binding sites on C5 all block convertase-mediated activation, implying a required conformational priming event."},"narrative":{"teleology":[{"year":1969,"claim":"Identification that C5 cleavage generates a potent leukocyte chemoattractant (C5a) established the first effector function of C5 beyond hemolysis and linked complement activation to cellular immune recruitment.","evidence":"In vitro chemotaxis assay with C5-derived fractions from human serum","pmids":["5765461"],"confidence":"High","gaps":["C5a structure unknown","receptor identity unknown","mechanism of C5 cleavage specificity unresolved"]},{"year":1978,"claim":"Determination of the complete 74-residue primary structure of C5a, including three disulfide bonds and C-terminal Arg74 as critical for chemotactic potency, provided the first molecular framework for C5a pharmacophore studies.","evidence":"Protein sequencing, carbohydrate analysis, and functional chemotaxis assays of purified human C5a","pmids":["690134","342601"],"confidence":"High","gaps":["Three-dimensional structure undetermined","receptor binding residues beyond Arg74 unknown"]},{"year":1985,"claim":"Identification of the C5a receptor on neutrophils (~40 kDa binding moiety) by affinity cross-linking demonstrated a specific, saturable receptor distinct from other chemoattractant receptors, and NMR studies confirmed the predicted four-helix bundle core of C5a.","evidence":"125I-C5a affinity cross-linking with SDS-PAGE on human PMN; 3D heteronuclear NMR of 15N-labeled recombinant C5a","pmids":["3997862","2730871"],"confidence":"High","gaps":["Receptor primary sequence unknown","G-protein coupling mechanism uncharacterized"]},{"year":1986,"claim":"Reconstitution of C5b-6/C5b-7 membrane insertion with defined lipid vesicles revealed that C6 and C7 bind the C5b α′-chain and that negatively charged phospholipids are required for initial membrane association, defining the assembly pathway of the MAC.","evidence":"Lipid vesicle binding assays, bimolecular kinetics, and activation energy measurements with purified complement components","pmids":["3801440"],"confidence":"High","gaps":["Full MAC (C5b-9) assembly and pore structure unresolved","membrane insertion mechanism of C8/C9 not addressed"]},{"year":1991,"claim":"Cloning of C5aR revealed it as a seven-transmembrane GPCR, immediately explaining its Gi-dependent signaling properties and enabling targeted genetic and pharmacological studies.","evidence":"cDNA cloning from U937/HL-60 cells, heterologous expression in COS-7 cells with radioligand binding confirmation","pmids":["1847994"],"confidence":"High","gaps":["Downstream signaling cascades not yet mapped","second C5a receptor (C5L2/C5aR2) unknown"]},{"year":1994,"claim":"Systematic mutagenesis of C5a defined a two-domain pharmacophore (10 charged core residues + C-terminal Arg74, with Lys19/20 critical), while C5aR signaling was mapped to Gi-coupled Ras/Raf/MEK/ERK and PKC-dependent pathways, connecting ligand structure to intracellular signaling architecture.","evidence":"Site-directed mutagenesis with Ca2+ mobilization and receptor binding; kinase activity assays with pertussis toxin and PKC modulators in neutrophils","pmids":["7987211","8112341","8090790"],"confidence":"High","gaps":["Structural basis of C5a-C5aR interaction at atomic resolution not yet available","receptor phosphorylation/desensitization cycle incomplete"]},{"year":1995,"claim":"Discovery that C5aR undergoes GRK-mediated phosphorylation (Gi-independent) and requires PP1/PP2A-dependent dephosphorylation for recycling/resensitization defined the regulatory cycle controlling C5a responsiveness.","evidence":"32P-phosphorylation, pertussis toxin, okadaic acid treatment, and receptor trafficking kinetics in differentiated HL-60 cells","pmids":["7706744"],"confidence":"High","gaps":["Specific GRK isoform identity unresolved","phosphorylation sites on C5aR not mapped"]},{"year":2001,"claim":"Identification of C5aR N-terminal tyrosine sulfation (Tyr11, Tyr14) as essential for C5a docking, combined with the finding that sublytic MAC activates ERK/PI3K/Akt and cell-cycle entry, established two-site receptor engagement and separated the signaling roles of C5a and C5b-9.","evidence":"35S-sulfate labeling and mutagenesis of C5aR with functional assays; ERK/Akt kinase assays and cell-cycle analysis after sublytic MAC treatment","pmids":["11342590","11414362"],"confidence":"High","gaps":["Atomic-resolution structure of C5a–C5aR complex not yet solved","MAC signaling receptor identity unclear"]},{"year":2002,"claim":"C5 convertase specificity was quantitatively explained by C3b surface density (>1000-fold Km shift), while phagocyte-derived serine proteases were shown to generate C5a independently of complement convertases, revealing parallel activation pathways for C5.","evidence":"Km determination for reconstituted convertases at varying C3b densities; incubation of activated phagocytes with C5 plus serine protease inhibitor panels","pmids":["12440962","12414531"],"confidence":"High","gaps":["Identity of phagocyte serine protease not determined","structural basis of C3b density-dependent allosteric switch unknown"]},{"year":2003,"claim":"Discovery that C5L2/C5aR2 binds C5a with high affinity but is obligately G-protein-uncoupled (DRY→DLC mutation), combined with genetic evidence that C5a/C3a drive liver regeneration via NF-κB/STAT-3, expanded C5 biology beyond immunity into regeneration and defined a second, non-signaling receptor.","evidence":"Pharmacological characterization of C5L2 (radioligand binding, cAMP, Ca2+, MAPK); complement-deficient mice with partial hepatectomy and C3a/C5a reconstitution","pmids":["12899627","12975457"],"confidence":"High","gaps":["C5L2 in vivo function unclear","mechanism of C5a-driven hepatocyte proliferation beyond cytokine induction not mapped"]},{"year":2005,"claim":"Genetic mapping of C5 (Hc locus) as the causal gene for hepatic fibrosis susceptibility, validated by transgenesis and C5aR antagonist treatment, established C5a-C5aR as a therapeutic target in fibrotic disease.","evidence":"Congenic mice, BAC transgenesis, C5aR small-molecule antagonist in vivo, human hepatitis C genetic association","pmids":["15995705"],"confidence":"High","gaps":["Fibrogenic cell type responding to C5a not definitively identified","mechanism of C5a-driven stellate cell activation unresolved"]},{"year":2007,"claim":"C5L2/C5aR2 was shown to have non-redundant pro-inflammatory roles in vivo (facilitating C5a signaling, mediating HMGB1 release in sepsis), resolving the initial characterization as merely a decoy receptor.","evidence":"C5L2-KO mice in LPS sepsis, OVA airway inflammation, and CLP sepsis models; HMGB1 ELISA; dual C5aR1/C5aR2 blockade","pmids":["17322907","18454156"],"confidence":"High","gaps":["Mechanism by which C5aR2 signals without G-protein coupling not defined","cell-type-specific roles of C5aR2 (macrophage vs. endothelium) not delineated"]},{"year":2014,"claim":"Discovery of the C5 p.Arg885His variant that retains hemolytic function but abolishes eculizumab binding explained clinical resistance in PNH patients, demonstrating that therapeutic anti-C5 antibodies target a defined epitope distinct from the convertase cleavage or MAC-assembly sites.","evidence":"Gene sequencing, hemolysis assays with mutant C5, eculizumab and N19-8 binding assays in PNH patient-derived samples","pmids":["24521109"],"confidence":"High","gaps":["Precise structural basis of eculizumab–C5 interaction not yet resolved at atomic level at this time","frequency of resistance variants in non-Asian populations unclear"]},{"year":2016,"claim":"Crystal structures of C5 bound to three structurally distinct inhibitors (tick OmCI-class proteins, eculizumab Fab) at non-overlapping sites—all blocking convertase activation—established that C5 requires a conformational priming event for cleavage, not merely enzyme access to the scissile bond.","evidence":"X-ray crystallography of C5–inhibitor complexes with competitive convertase inhibition assays","pmids":["27018802"],"confidence":"High","gaps":["Nature of the conformational priming event uncharacterized","C5 convertase–C5 complex structure not solved"]},{"year":2018,"claim":"Crystal structures of C5aR1 with orthosteric (PMX53) and allosteric (avacopan) antagonists revealed two druggable binding sites and a novel helix-8 conformation, providing the structural basis for rational C5aR1 drug design.","evidence":"X-ray crystallography of C5aR1 ternary complexes, computational docking, cell-based signaling assays","pmids":["29867214"],"confidence":"High","gaps":["Active-state C5aR1 structure with C5a not available","structural basis of biased agonism/antagonism at C5aR1 unknown"]},{"year":2019,"claim":"C5aR2 was revealed to function as a transcytosis receptor on endothelial cells, transporting C5a from tissue to vascular lumen to initiate C5aR1-mediated neutrophil arrest, while simultaneously acting as a negative regulator of C5aR1 via physical interaction with β-arrestin—resolving the paradox of C5aR2's dual pro- and anti-inflammatory roles.","evidence":"Intravital microscopy with C5aR2-KO mice; co-immunoprecipitation of C5aR2–C5aR1–β-arrestin; MPO-ANCA GN model with receptor KOs","pmids":["31076525","24179165"],"confidence":"High","gaps":["Structural basis of C5aR2 transcytosis mechanism unresolved","endothelial vs. leukocyte C5aR2 contributions not fully dissected"]},{"year":2023,"claim":"Phagocyte-intrinsic C5 production (not only liver-derived C5) was shown to be a critical substrate source for C5a-C5aR1 antifungal defense, with C5aR1 signaling promoting phagocyte survival via ERK/Akt/mTOR-dependent metabolic reprogramming.","evidence":"C5ar1-KO mice with systemic candidiasis, RNA-seq, metabolomics, mTOR pathway inhibition, phagocyte-specific C5 expression analysis","pmids":["37220746"],"confidence":"High","gaps":["Protease responsible for phagocyte-autonomous C5 cleavage not identified","relative contribution of local vs. hepatic C5 in other infectious or inflammatory contexts unknown"]},{"year":null,"claim":"Key unresolved questions include the atomic structure of the C5 convertase–C5 complex (and the nature of the conformational priming event required for cleavage), the identity of the phagocyte serine protease that cleaves C5, the active-state structure of C5aR1 bound to C5a, and the receptor/mechanism by which sublytic MAC activates intracellular signaling.","evidence":"","pmids":[],"confidence":"High","gaps":["C5 convertase–C5 complex structure not solved","Phagocyte C5-cleaving protease not identified","Active-state C5a–C5aR1 structure unavailable","MAC signaling receptor unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,7,14,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[24,50]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,3,7,24,26]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,11,19,23]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,13,16,18,28,30,40,47,49]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,20,23,28,34,46]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[3,26]}],"complexes":["MAC (C5b-9)","C5b-6","C5b-7"],"partners":["C5AR1","C5AR2","C6","C7","C3B","CFHR1"],"other_free_text":[]},"mechanistic_narrative":"Complement C5 is a central effector of innate immunity whose proteolytic cleavage generates two functionally distinct arms of the terminal complement pathway: the anaphylatoxin C5a and the MAC-initiating fragment C5b. C5 is cleaved by C5 convertases whose specificity is allosterically switched from C3 to C5 by increasing C3b surface density (>1000-fold Km shift), and also by non-complement serine proteases from activated phagocytes and cancer cells [PMID:12440962, PMID:12414531, PMID:25050844]. C5a signals through the Gi-coupled receptor C5aR1 (activating Ras/Raf/MEK/ERK and PI3K/Akt cascades) to drive neutrophil chemotaxis, mast cell migration, inflammasome priming, Fcγ receptor rebalancing, and platelet CXCL4 release, while C5aR2 modulates this signaling as both an endothelial transcytosis receptor delivering C5a into the vascular lumen and a negative regulator of C5aR1 via β-arrestin interaction [PMID:8090790, PMID:31076525, PMID:24179165]. C5b sequentially recruits C6 and C7 through its α′-chain cysteine-rich domains to form membrane-inserted MAC (C5b-9), which at sublytic concentrations activates ERK, PI3K/Akt, and cell-cycle entry independently of C5a signaling [PMID:1387399, PMID:15855657, PMID:11414362]."},"prefetch_data":{"uniprot":{"accession":"P01031","full_name":"Complement C5","aliases":["C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4"],"length_aa":1676,"mass_kda":188.3,"function":"Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279) Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291) Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed:8182049, PubMed:9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:36806352, PubMed:37852260, PubMed:37169960, PubMed:8182049, PubMed:9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed:342601, PubMed:37852260, PubMed:37169960, PubMed:5765461, PubMed:8182049, PubMed:9553099)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01031/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/C5","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/C5","total_profiled":1310},"omim":[{"mim_id":"621104","title":"DIHYDROURIDINE SYNTHASE 3-LIKE PROTEIN; DUS3L","url":"https://www.omim.org/entry/621104"},{"mim_id":"619309","title":"PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1F; PPM1F","url":"https://www.omim.org/entry/619309"},{"mim_id":"619227","title":"VERTEBRAL, CARDIAC, TRACHEOESOPHAGEAL, RENAL, AND LIMB DEFECTS; VCTERL","url":"https://www.omim.org/entry/619227"},{"mim_id":"618843","title":"LAYILIN; LAYN","url":"https://www.omim.org/entry/618843"},{"mim_id":"617898","title":"MULTIPLE SYNOSTOSES SYNDROME 4; SYNS4","url":"https://www.omim.org/entry/617898"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":418.8}],"url":"https://www.proteinatlas.org/search/C5"},"hgnc":{"alias_symbol":["CPAMD4","C5a","C5b"],"prev_symbol":[]},"alphafold":{"accession":"P01031","domains":[{"cath_id":"2.60.40.1930","chopping":"23-121","consensus_level":"high","plddt":87.6803,"start":23,"end":121},{"cath_id":"2.60.40.1930","chopping":"470-567","consensus_level":"medium","plddt":85.7159,"start":470,"end":567},{"cath_id":"2.20.130.20","chopping":"569-619_679-740_754-822","consensus_level":"medium","plddt":78.6724,"start":569,"end":822},{"cath_id":"2.60.40.10","chopping":"829-931","consensus_level":"high","plddt":77.0398,"start":829,"end":931},{"cath_id":"2.60.120.1540","chopping":"934-983_1313-1370","consensus_level":"medium","plddt":84.7881,"start":934,"end":1370},{"cath_id":"1.50.10.20","chopping":"984-1306","consensus_level":"medium","plddt":86.825,"start":984,"end":1306},{"cath_id":"2.60.40.690","chopping":"1375-1389_1397-1510","consensus_level":"medium","plddt":82.448,"start":1375,"end":1510},{"cath_id":"2.40.50.120","chopping":"1533-1675","consensus_level":"medium","plddt":81.8884,"start":1533,"end":1675}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01031","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01031-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01031-F1-predicted_aligned_error_v6.png","plddt_mean":81.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=C5","jax_strain_url":"https://www.jax.org/strain/search?query=C5"},"sequence":{"accession":"P01031","fasta_url":"https://rest.uniprot.org/uniprotkb/P01031.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01031/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01031"}},"corpus_meta":[{"pmid":"1847994","id":"PMC_1847994","title":"The chemotactic receptor for human C5a anaphylatoxin.","date":"1991","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1847994","citation_count":605,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16452172","id":"PMC_16452172","title":"Drusen complement components C3a and C5a promote choroidal neovascularization.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16452172","citation_count":534,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10811844","id":"PMC_10811844","title":"Predominant role for C5b-9 in renal ischemia/reperfusion injury.","date":"2000","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10811844","citation_count":385,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8011297","id":"PMC_8011297","title":"C5A anaphylatoxin and its seven transmembrane-segment receptor.","date":"1994","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8011297","citation_count":339,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12975457","id":"PMC_12975457","title":"The proinflammatory mediators C3a and C5a are essential for liver regeneration.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12975457","citation_count":335,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17603557","id":"PMC_17603557","title":"Function, structure and therapeutic potential of complement C5a receptors.","date":"2007","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17603557","citation_count":317,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18454156","id":"PMC_18454156","title":"Functional roles for C5a receptors in sepsis.","date":"2008","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18454156","citation_count":310,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24521109","id":"PMC_24521109","title":"Genetic variants in C5 and poor response to eculizumab.","date":"2014","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24521109","citation_count":307,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24179165","id":"PMC_24179165","title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN.","date":"2013","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/24179165","citation_count":277,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8779720","id":"PMC_8779720","title":"The C5a chemoattractant receptor mediates mucosal defence to infection.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8779720","citation_count":266,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9108406","id":"PMC_9108406","title":"C3a and C5a stimulate chemotaxis of human mast cells.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9108406","citation_count":254,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21549429","id":"PMC_21549429","title":"Inhibiting the C5-C5a receptor axis.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21549429","citation_count":240,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12899627","id":"PMC_12899627","title":"C5L2, a nonsignaling C5A binding protein.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12899627","citation_count":211,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17322907","id":"PMC_17322907","title":"C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17322907","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22797180","id":"PMC_22797180","title":"C3a and C5a promote renal ischemia-reperfusion injury.","date":"2012","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/22797180","citation_count":182,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11939578","id":"PMC_11939578","title":"Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.","date":"2002","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11939578","citation_count":177,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23239822","id":"PMC_23239822","title":"C5L2: a controversial receptor of complement anaphylatoxin, C5a.","date":"2012","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/23239822","citation_count":169,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12414531","id":"PMC_12414531","title":"Generation of C5a by phagocytic cells.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12414531","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12093893","id":"PMC_12093893","title":"Increased C5a receptor expression in sepsis.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12093893","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19464229","id":"PMC_19464229","title":"Complement component 5a (C5a).","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19464229","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2912983","id":"PMC_2912983","title":"Characterization of a receptor for C5a anaphylatoxin on human eosinophils.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2912983","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8288945","id":"PMC_8288945","title":"Membrane signaling by complement C5b-9, the membrane attack complex.","date":"1993","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/8288945","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18227853","id":"PMC_18227853","title":"Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2.","date":"2008","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18227853","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20588003","id":"PMC_20588003","title":"The harmful role of c5a on innate immunity in sepsis.","date":"2010","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20588003","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29867214","id":"PMC_29867214","title":"Orthosteric and allosteric action of the C5a receptor antagonists.","date":"2018","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29867214","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8090790","id":"PMC_8090790","title":"Mapping of the C5a receptor signal transduction network in human neutrophils.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8090790","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31978221","id":"PMC_31978221","title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31978221","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11414362","id":"PMC_11414362","title":"Role of the C5b-9 complement complex in cell cycle and apoptosis.","date":"2001","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11414362","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27018802","id":"PMC_27018802","title":"Structural basis for therapeutic inhibition of complement C5.","date":"2016","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27018802","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22651932","id":"PMC_22651932","title":"Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis.","date":"2012","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22651932","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12440962","id":"PMC_12440962","title":"Structure and function of complement C5 convertase enzymes.","date":"2002","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/12440962","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19189071","id":"PMC_19189071","title":"Functions of C5a receptors.","date":"2009","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/19189071","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14676676","id":"PMC_14676676","title":"Role of C5a-C5aR interaction in sepsis.","date":"2004","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/14676676","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37220746","id":"PMC_37220746","title":"C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection.","date":"2023","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/37220746","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25324545","id":"PMC_25324545","title":"Peptidyl arginine deiminase from Porphyromonas gingivalis abolishes anaphylatoxin C5a activity.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25324545","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20808780","id":"PMC_20808780","title":"Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20808780","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11342590","id":"PMC_11342590","title":"Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor.","date":"2001","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11342590","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10602324","id":"PMC_10602324","title":"Pharmacological characterization of antagonists of the C5a receptor.","date":"1999","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10602324","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10698342","id":"PMC_10698342","title":"Expression of the anaphylatoxin C5a receptor in non-myeloid cells.","date":"1999","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10698342","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20031321","id":"PMC_20031321","title":"Nociceptive sensitization by complement C5a and C3a in mouse.","date":"2009","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/20031321","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17243489","id":"PMC_17243489","title":"Drug evaluation: the C5a receptor antagonist PMX-53.","date":"2006","source":"Current opinion in molecular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17243489","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6222137","id":"PMC_6222137","title":"Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments.","date":"1983","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6222137","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3997862","id":"PMC_3997862","title":"Identification of the polymorphonuclear leukocyte C5a receptor.","date":"1985","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3997862","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26245757","id":"PMC_26245757","title":"Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome.","date":"2015","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26245757","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28706957","id":"PMC_28706957","title":"The Controversial C5a Receptor C5aR2: Its Role in Health and Disease.","date":"2017","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/28706957","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23576881","id":"PMC_23576881","title":"New developments in C5a receptor signaling.","date":"2012","source":"Cell health and cytoskeleton","url":"https://pubmed.ncbi.nlm.nih.gov/23576881","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27108698","id":"PMC_27108698","title":"Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.","date":"2016","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27108698","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3992245","id":"PMC_3992245","title":"Model structure for the inflammatory protein C5a.","date":"1985","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/3992245","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25262158","id":"PMC_25262158","title":"Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood.","date":"2014","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/25262158","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29259684","id":"PMC_29259684","title":"Complement-targeted therapy: development of C5- and C5a-targeted inhibition.","date":"2016","source":"Inflammation and regeneration","url":"https://pubmed.ncbi.nlm.nih.gov/29259684","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23233853","id":"PMC_23233853","title":"New insights for C5a and C5a receptors in sepsis.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23233853","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30569594","id":"PMC_30569594","title":"Critical role of C5a in sickle cell disease.","date":"2019","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/30569594","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21630250","id":"PMC_21630250","title":"TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21630250","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32327104","id":"PMC_32327104","title":"Complement C5 Protein as a Marker of Subclinical Atherosclerosis.","date":"2020","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/32327104","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24327134","id":"PMC_24327134","title":"C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy.","date":"2013","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24327134","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25050844","id":"PMC_25050844","title":"Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25050844","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18728577","id":"PMC_18728577","title":"Protective effect of C5a receptor inhibition after murine reperfused stroke.","date":"2008","source":"Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/18728577","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26673966","id":"PMC_26673966","title":"A novel long non-coding RNA in the rheumatoid arthritis risk locus TRAF1-C5 influences C5 mRNA levels.","date":"2015","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26673966","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24716540","id":"PMC_24716540","title":"Direct decarboxylation of 5-carboxylcytosine by DNA C5-methyltransferases.","date":"2014","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/24716540","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2681931","id":"PMC_2681931","title":"Renal injury in DOCA-salt hypertensive C5-sufficient and C5-deficient mice.","date":"1989","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/2681931","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35820938","id":"PMC_35820938","title":"Modulation of C5a-C5aR1 signaling alters the dynamics of AD progression.","date":"2022","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/35820938","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24260573","id":"PMC_24260573","title":"Complement C3 and C5 deficiency affects fracture healing.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24260573","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23603337","id":"PMC_23603337","title":"Pulp progenitor cell recruitment is selectively guided by a C5a gradient.","date":"2013","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/23603337","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34099640","id":"PMC_34099640","title":"The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34099640","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20217457","id":"PMC_20217457","title":"C5a promotes migration, proliferation, and vessel formation in endothelial cells.","date":"2010","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/20217457","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36989901","id":"PMC_36989901","title":"The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36989901","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11367526","id":"PMC_11367526","title":"Structure/function of C5 convertases of complement.","date":"2001","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11367526","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22058413","id":"PMC_22058413","title":"C5a regulates NKT and NK cell functions in sepsis.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22058413","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20207017","id":"PMC_20207017","title":"Inhibition of C5a receptor alleviates experimental CNS lupus.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20207017","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25124749","id":"PMC_25124749","title":"Complement factor C5a induces atherosclerotic plaque disruptions.","date":"2014","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25124749","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11356221","id":"PMC_11356221","title":"Cloning and purification of the rainbow trout fifth component of complement (C5).","date":"2001","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11356221","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3351304","id":"PMC_3351304","title":"A direct in vivo comparison of the inflammatory properties of human C5a and C5a des Arg in human skin.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3351304","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1387399","id":"PMC_1387399","title":"Formation and structure of the C5b-7 complex of the lytic pathway of complement.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1387399","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11530215","id":"PMC_11530215","title":"Hexuronyl C5-epimerases in alginate and glycosaminoglycan biosynthesis.","date":"2001","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/11530215","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21677637","id":"PMC_21677637","title":"Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury.","date":"2011","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/21677637","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21736743","id":"PMC_21736743","title":"Increased local concentration of complement C5a contributes to incisional pain in mice.","date":"2011","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/21736743","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26324770","id":"PMC_26324770","title":"Retinal Pigment Epithelial Cells Mitigate the Effects of Complement Attack by Endocytosis of C5b-9.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26324770","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7987211","id":"PMC_7987211","title":"The pharmacophore of the human C5a anaphylatoxin.","date":"1994","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/7987211","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8112341","id":"PMC_8112341","title":"Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.","date":"1994","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8112341","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31076525","id":"PMC_31076525","title":"Atypical complement receptor C5aR2 transports C5a to initiate neutrophil adhesion and inflammation.","date":"2019","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31076525","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7706744","id":"PMC_7706744","title":"Phosphorylation, dephosphorylation, and recycling of the C5a receptor in differentiated HL60 cells.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7706744","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15100315","id":"PMC_15100315","title":"Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15100315","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10092084","id":"PMC_10092084","title":"Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10092084","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25912155","id":"PMC_25912155","title":"Orai1 controls C5a-induced neutrophil recruitment in inflammation.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25912155","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3801440","id":"PMC_3801440","title":"Interaction of complement proteins C5b-6 and C5b-7 with phospholipid vesicles: effects of phospholipid structural features.","date":"1986","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3801440","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35029045","id":"PMC_35029045","title":"The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.","date":"2022","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/35029045","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8417126","id":"PMC_8417126","title":"Relationship of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8417126","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29914696","id":"PMC_29914696","title":"Role of complement C5a and histones in septic cardiomyopathy.","date":"2018","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29914696","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15855657","id":"PMC_15855657","title":"Activation of the extracellular signal-regulated kinase by complement C5b-9.","date":"2005","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15855657","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2951551","id":"PMC_2951551","title":"Leukocyte C5a receptor modulation during hemodialysis.","date":"1987","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/2951551","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8015436","id":"PMC_8015436","title":"Phylogeny of the C3/C4/C5 complement-component gene family indicates that C5 diverged first.","date":"1994","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/8015436","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31871188","id":"PMC_31871188","title":"An inhibitor of complement C5 provides structural insights into activation.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31871188","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11251209","id":"PMC_11251209","title":"Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage.","date":"2001","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11251209","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7478119","id":"PMC_7478119","title":"The pathogenetic significance of C5b-9 in IgA nephropathy.","date":"1995","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/7478119","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32638512","id":"PMC_32638512","title":"ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a.","date":"2020","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32638512","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35598724","id":"PMC_35598724","title":"Involvement of complement peptides C3a and C5a in osteoarthritis pathology.","date":"2022","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/35598724","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26045819","id":"PMC_26045819","title":"CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26045819","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18275159","id":"PMC_18275159","title":"Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor.","date":"2008","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18275159","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9631067","id":"PMC_9631067","title":"Elucidation of gene function using C-5 propyne antisense oligonucleotides.","date":"1996","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/9631067","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32101978","id":"PMC_32101978","title":"Neutralizing Complement C5a Protects Mice with Pneumococcal Pulmonary Sepsis.","date":"2020","source":"Anesthesiology","url":"https://pubmed.ncbi.nlm.nih.gov/32101978","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24390342","id":"PMC_24390342","title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24390342","citation_count":1778,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26082779","id":"PMC_26082779","title":"Complement System Part I - Molecular Mechanisms of Activation and Regulation.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26082779","citation_count":1275,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20453842","id":"PMC_20453842","title":"Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20453842","citation_count":1018,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3052276","id":"PMC_3052276","title":"Molecular organization and function of the complement system.","date":"1988","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3052276","citation_count":716,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17634448","id":"PMC_17634448","title":"Complement C3 variant and the risk of age-related macular degeneration.","date":"2007","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17634448","citation_count":690,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17804836","id":"PMC_17804836","title":"TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study.","date":"2007","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17804836","citation_count":675,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"342601","id":"PMC_342601","title":"Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.","date":"1978","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/342601","citation_count":640,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14566334","id":"PMC_14566334","title":"An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice.","date":"2003","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14566334","citation_count":512,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22020285","id":"PMC_22020285","title":"Image-based genome-wide siRNA screen identifies selective autophagy factors.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22020285","citation_count":405,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"5765461","id":"PMC_5765461","title":"A neutrophil chemotactic factor from human C'5.","date":"1969","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/5765461","citation_count":319,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2730871","id":"PMC_2730871","title":"Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a.","date":"1989","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2730871","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11752456","id":"PMC_11752456","title":"Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11752456","citation_count":300,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19503088","id":"PMC_19503088","title":"REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19503088","citation_count":287,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23028051","id":"PMC_23028051","title":"Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23028051","citation_count":240,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"690134","id":"PMC_690134","title":"Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.","date":"1978","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/690134","citation_count":235,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12488432","id":"PMC_12488432","title":"C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12488432","citation_count":228,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24554772","id":"PMC_24554772","title":"Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24554772","citation_count":228,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17703412","id":"PMC_17703412","title":"Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17703412","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17880261","id":"PMC_17880261","title":"A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis.","date":"2007","source":"PLoS medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17880261","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19528535","id":"PMC_19528535","title":"Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19528535","citation_count":221,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15995705","id":"PMC_15995705","title":"Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans.","date":"2005","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15995705","citation_count":211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19110536","id":"PMC_19110536","title":"Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus.","date":"2008","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19110536","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46021,"output_tokens":8348,"usd":0.131641},"stage2":{"model":"claude-opus-4-6","input_tokens":12202,"output_tokens":5936,"usd":0.314115},"total_usd":0.917811,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59238,"output_tokens":12833,"usd":0.185105},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":16790,"output_tokens":4294,"usd":0.28695}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"The human C5a receptor (C5aR/CD88) was cloned from U937 and HL-60 cells and identified as a G-protein-coupled receptor with seven transmembrane domains; high-affinity C5a binding was confirmed by expression in COS-7 cells.\",\n      \"method\": \"Molecular cloning, heterologous expression, radioligand binding assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with functional receptor binding validation in heterologous system; highly cited foundational paper\",\n      \"pmids\": [\"1847994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Limited trypsin hydrolysis of C5 alpha-chain generates fragments C5α1 and C5α5 (remaining disulfide-bonded to C5), conferring C5a-like chemotactic and lysosomal enzyme-releasing activities without releasing free C5a polypeptide; non-complement serine proteases (thrombin, plasmin, elastase) similarly activate C5.\",\n      \"method\": \"In vitro proteolysis, SDS-PAGE, gel filtration, functional chemotaxis and enzyme-release assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with structural and functional characterization; multiple protease conditions tested\",\n      \"pmids\": [\"6222137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"The C5a receptor on human polymorphonuclear leukocytes (PMN) was identified by affinity cross-linking of 125I-C5a with disuccinimidyl suberate, revealing a receptor binding moiety of ~40 kDa (complex ~52 kDa); binding was specific and competed by unlabeled C5a but not by fMLP or LTB4.\",\n      \"method\": \"Affinity cross-linking, SDS-PAGE, radioligand binding\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical identification of receptor with competition controls; foundational receptor characterization\",\n      \"pmids\": [\"3997862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Human eosinophils express two C5a receptor populations (high-affinity ~3×10⁻¹¹ M, 15,000–20,000 sites/cell; low-affinity ~10⁻⁷ M, ~375,000 sites/cell) distinct from the single neutrophil C5a receptor population, with the eosinophil receptor cross-linking complex migrating at 60–65 kDa vs. 50–52 kDa for neutrophils.\",\n      \"method\": \"125I-C5a radioligand binding (Scatchard analysis), covalent cross-linking, SDS-PAGE, cyanogen bromide cleavage\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical methods identifying distinct receptor populations on two cell types\",\n      \"pmids\": [\"2912983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"C5 and C5b interact with C6 and C7 through the α'-chain of C5b to form the C5b-7 intermediate of the membrane attack complex; the carboxyl-terminal cysteine-rich domains of C6 and C7 associate preferentially with the C5b α'-chain, while C5d (C-terminal fragment of C5b) mediates C5 binding to C3b.\",\n      \"method\": \"Limited proteolysis, circular dichroism, polyclonal antibody blocking assays, chemical cross-linking with photoreactive reagent, solid-phase binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal structural and functional methods mapping interaction domains\",\n      \"pmids\": [\"1387399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Sublytic C5b-9 assembly on nucleated cell membranes generates non-lethal signals including Ca²⁺ influx, cAMP, inositol phosphates, and arachidonate metabolites; cells escape lysis by endocytosis and membrane shedding of C5b-9.\",\n      \"method\": \"Cell signaling assays (Ca²⁺ flux, second messenger measurements), membrane biology experiments\",\n      \"journal\": \"Immunologic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling readouts, but review summarizing prior experimental work\",\n      \"pmids\": [\"8288945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"C5a receptor activation in human neutrophils signals through Gi proteins to activate Ras, B-Raf and Raf-1, which phosphorylate MEK-1, leading to MAP kinase activation; protein kinase C-dependent and -independent pathways both contribute, and protein kinase A activation inhibits Raf-1 and B-Raf.\",\n      \"method\": \"Pertussis toxin treatment, kinase activity assays, GTP exchange assays, PKC/PKA modulation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple kinase pathway components mapped with pharmacological inhibitors and direct enzyme assays\",\n      \"pmids\": [\"8090790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Mutational analysis of human C5a identified ten noncontiguous charged residues in the four-helix core domain and the C-terminal Arg74 as contributing to the pharmacophore for receptor binding and calcium mobilization; Arg74 substitution produced the largest single effect on activity.\",\n      \"method\": \"Site-directed mutagenesis, receptor binding assay, intracellular calcium mobilization assay, C3a/C5a hybrid construction\",\n      \"journal\": \"Protein science : a publication of the Protein Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with multiple functional readouts defining ligand pharmacophore\",\n      \"pmids\": [\"7987211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Des-Arg74-C5a retains the three-dimensional structure of wild-type C5a (confirmed by CD spectroscopy) but displays only 3–4% functional activity in myeloperoxidase release; Lys19 and/or Lys20 in the N-terminus are required for receptor interaction (~30-fold reduction on double Ala substitution), while Arg40 and Pro45 in the core loop are not essential.\",\n      \"method\": \"Site-directed mutagenesis, CD spectroscopy, myeloperoxidase release assay, Xenopus oocyte electrophysiology, guinea pig ileum contraction assay\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with structural validation (CD) and multiple functional assays across species\",\n      \"pmids\": [\"8112341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Agonist-occupied C5a receptor is phosphorylated predominantly by a G-protein-coupled receptor kinase independently of Gi activation; phosphorylation is transient (half-life ~30–40 min), reversed by protein phosphatases 1/2A, and dephosphorylation is coupled to receptor recycling to the plasma membrane for resensitization.\",\n      \"method\": \"Pertussis toxin treatment, [32P]-phosphate incorporation, okadaic acid inhibition, receptor internalization/recycling assays in differentiated HL60 cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic dissection of phosphorylation/dephosphorylation cycle with pharmacological tools\",\n      \"pmids\": [\"7706744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"C5a receptor-deficient mice fail to clear intrapulmonary Pseudomonas aeruginosa despite increased neutrophil influx, demonstrating a non-redundant role for C5aR in neutrophil-mediated mucosal host defense in the lung that is distinct from simple neutrophil recruitment.\",\n      \"method\": \"C5aR knockout mice, intrapulmonary bacterial challenge (P. aeruginosa), survival analysis, neutrophil counting\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout with specific infection model and cellular phenotype; highly cited\",\n      \"pmids\": [\"8779720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In renal ischemia/reperfusion injury, C5-deficient and C6-deficient (but not C4-deficient) mice are protected, and reconstitution of C6-deficient mice with C6 alone restores injury; blocking C5a generation in C6-deficient mice provides no additional protection, establishing that the C5b-9 membrane attack complex (not C5a-mediated neutrophil recruitment) is the primary complement effector causing tubular epithelial cell injury.\",\n      \"method\": \"Complement-deficient mouse models, renal artery occlusion, antibody blockade, C6 reconstitution, histology, myeloperoxidase assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with reconstitution experiment and antibody blockade across multiple deficiencies\",\n      \"pmids\": [\"10811844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The tyrosines at positions 11 and 14 of the C5a receptor N-terminus are posttranslationally sulfated, and these sulfate moieties are critical for C5a binding and calcium mobilization; a two-site binding model is supported where the sulfated N-terminal region mediates initial C5a docking.\",\n      \"method\": \"Tyrosine sulfation site-directed mutagenesis, calcium mobilization assay, small peptide agonist assay, peptide inhibition assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — PTM identification with mutagenesis and functional validation demonstrating mechanistic basis for ligand docking\",\n      \"pmids\": [\"11342590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Sublytic C5b-9 activates the cell cycle and promotes cell survival via Gi-mediated ERK1 activation and PI3K/Akt pathway activation (which inhibits apoptosis through BAD regulation); it also reverses differentiated phenotype of postmitotic cells.\",\n      \"method\": \"Cell cycle analysis, kinase assays (ERK, PI3K, Akt), signaling inhibitor studies\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling pathway readouts but review format summarizing experimental work\",\n      \"pmids\": [\"11414362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Activated blood neutrophils and alveolar macrophages generate C5a from purified C5 via a serine protease-dependent mechanism; the activity is blocked by serine protease inhibitors and by transcription/translation inhibitors in macrophages, indicating newly synthesized serine protease activity is required.\",\n      \"method\": \"C5a generation assay with purified C5, protease inhibitor profiling, actinomycin D/cycloheximide pretreatment, chemotaxis bioassay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzyme assay with mechanistic dissection using multiple inhibitor classes and protein synthesis inhibitors\",\n      \"pmids\": [\"12414531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Carboxypeptidase R (thrombin-activatable fibrinolysis inhibitor/TAFI) removes the C-terminal arginine from C5a octapeptide much more efficiently than carboxypeptidase N, identifying CPR as a major inactivator of C5a anaphylatoxin activity.\",\n      \"method\": \"In vitro enzymatic assay comparing CPR and CPN cleavage of C5a C-terminal octapeptide\",\n      \"journal\": \"Microbiology and immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzyme activity comparison establishing CPR as primary C5a inactivator\",\n      \"pmids\": [\"11939578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"C5 convertases switch specificity from C3 to C5 cleavage when additional C3b molecules deposit on cell surfaces: monomeric C3b convertases have poor C5 affinity (Km ~25 μM), but C3b-C3b or C4b-C3b complexes lower the Km for C5 more than 1000-fold, enabling efficient C5b-9 production.\",\n      \"method\": \"Enzyme kinetics (Km, Vmax determination), reconstituted convertase assays, surface C3b density manipulation\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative enzyme kinetics with mechanistic explanation of convertase substrate switching\",\n      \"pmids\": [\"12440962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C5L2 (GPR77) is a high-affinity C5a binding protein that is obligately uncoupled from heterotrimeric G proteins due to an Arg→Leu substitution in the DRY motif of its third transmembrane segment; it shows weak phosphorylation after C5a binding but does not induce MAP kinase activation, calcium flux, chemotaxis, or transcriptional responses to C5a.\",\n      \"method\": \"Heterologous receptor expression, radioligand binding, MAP kinase assay, calcium flux assay, chemotaxis assay, gene expression microarray, biophysical binding kinetics\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple functional assays with structural rationale (DRY motif mutation); comprehensive characterization\",\n      \"pmids\": [\"12899627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C5a and C5aR signaling is required for liver regeneration after partial hepatectomy; C5-deficient mice show impaired hepatocyte proliferation associated with suppressed IL-6/TNF-α induction and attenuated NF-κB/STAT-3 activation; combined C3a and C5a reconstitution rescues the phenotype in dual C3/C5-deficient mice.\",\n      \"method\": \"C3/C5 knockout mice, partial hepatectomy model, C3a/C5a reconstitution, NF-κB/STAT-3 activation assays, cytokine measurement\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with reconstitution and defined signaling pathway readouts\",\n      \"pmids\": [\"12975457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"C5b-9 activates ERK in glomerular epithelial cells via a Ras-dependent, PKC-independent pathway; ERK activation requires intact actin cytoskeleton and is inhibited by constitutively active RhoA or Rho-associated kinase inhibition; activated ERK phosphorylates cytosolic phospholipase A2 and MAPKAP kinase-2 but not Elk-1.\",\n      \"method\": \"Dominant-negative Ras expression, kinase phosphorylation assays, actin disassembly drugs (cytochalasin D, latrunculin B), RhoA/ROCK modulation in glomerular epithelial cells\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple mechanistic interventions mapping signaling pathway from C5b-9 to specific substrates\",\n      \"pmids\": [\"15855657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"C5L2 gene-targeted mice show that C5L2 facilitates C5a signaling in neutrophils, macrophages, and fibroblasts in vitro and promotes inflammatory cell infiltration in vivo; C5L2 also optimizes C3a-induced signals, and C5L2-deficient mice phenocopy C3aR-deficient mice in LPS-induced septic shock susceptibility, airway hyper-responsiveness, and haematopoietic regeneration.\",\n      \"method\": \"Gene targeting (C5L2 knockout), in vitro neutrophil/macrophage/fibroblast signaling assays, in vivo inflammatory cell infiltration models, LPS sepsis model, OVA asthma model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean gene knockout with multiple in vitro and in vivo phenotypic readouts across different cell types and disease models\",\n      \"pmids\": [\"17322907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In cecal ligation and puncture sepsis, both C5aR and C5L2 contribute synergistically to harmful outcomes; C5L2 (but not C5aR) is specifically required for in vivo and in vitro HMGB1 release; combined blockade of both receptors is uniquely protective in high-grade sepsis.\",\n      \"method\": \"C5aR/C5L2 knockout mice, antibody blockade, CLP sepsis model, HMGB1 measurement, survival analysis\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal knockout and antibody blockade experiments with specific mechanistic readout (HMGB1 release)\",\n      \"pmids\": [\"18454156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A missense C5 mutation at Arg885 (p.Arg885His or p.Arg885Cys) renders C5 incapable of binding eculizumab while retaining hemolytic function, explaining poor eculizumab response; in vitro hemolysis due to mutant C5 is blocked by antibody N19-8 that binds a different C5 epitope.\",\n      \"method\": \"C5 gene sequencing, in vitro hemolysis assay with wild-type vs. mutant C5, antibody binding/blocking assays\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional in vitro assay with structural mutation mapping defining antibody binding site\",\n      \"pmids\": [\"24521109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cancer cell membrane-bound serine proteases cleave C5 to generate C5a; this activity is blocked by aprotinin and a paired basic amino acid site-directed inhibitor but not by cysteine, acid, or metalloprotease inhibitors; cancer cell-released C5a enhances cancer cell invasion via C5aR.\",\n      \"method\": \"C5a generation assay in cancer cell conditioned media, protease inhibitor profiling, invasion assay with anti-C5a antibody, C5aR-expressing cell lines\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct enzymatic assay with inhibitor profiling and functional consequence measured\",\n      \"pmids\": [\"25050844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Peptidylarginine deiminase (PPAD) from Porphyromonas gingivalis citrullinates C-terminal Arg74 of C5a, disabling its chemotactic activity and calcium signaling via C5aR; PPAD-expressing outer membrane vesicles generate fully citrullinated C5a from intact C5.\",\n      \"method\": \"In vitro PPAD treatment of C5a, mass spectrometry, neutrophil chemotaxis assay, intracellular calcium assay in C5aR-transfected U937 cells, outer membrane vesicle treatment of C5\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic modification with mass spec identification and multiple functional readouts\",\n      \"pmids\": [\"25324545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of human C5 in complex with the tick-derived inhibitors OmCI and eculizumab Fab reveal three distinct binding sites on C5 that all prevent C5 convertase activation; the inhibitor-binding sites and competitive convertase inhibition conflict with steric-inhibition models, suggesting a priming event is required for C5 activation.\",\n      \"method\": \"Cryo-EM and X-ray crystallography of C5-inhibitor complexes, competitive convertase inhibition assays\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple crystal structures with functional validation; defines mechanism of C5 activation\",\n      \"pmids\": [\"27018802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structures of human C5aR in ternary complexes with peptide antagonist PMX53 and non-peptide antagonists (avacopan or NDT9513727) reveal orthosteric action of PMX53 stabilizing the receptor and allosteric action of non-peptide antagonists at a distinct binding site; structural comparison identifies a novel conformation of helix 8 relevant to receptor activation.\",\n      \"method\": \"X-ray crystallography, computational docking, cell-based signaling assays, biophysical characterization\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with functional validation defining orthosteric and allosteric mechanisms\",\n      \"pmids\": [\"29867214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The atypical C5a receptor C5aR2 expressed on endothelial cells functions as a transporter, moving C5a from the tissue into the vessel lumen; transported C5a then initiates C5aR1-dependent neutrophil arrest, while ACKR1 similarly transports CXCL2 for CXCR2-dependent neutrophil transmigration.\",\n      \"method\": \"Intravital microscopy in live mice (immune complex-induced arthritis model), C5aR2 and ACKR1 knockout mice, C5a tracking\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo real-time imaging with knockout validation establishing transcytosis function of C5aR2\",\n      \"pmids\": [\"31076525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CryoEM structure of C5 in complex with tick-derived CirpT inhibitor, with X-ray crystal structure of the C5_MG4-CirpT complex at 2.7Å, reveals that CirpT binds the peripheral macroglobulin domain 4 (MG4) of C5 to inhibit activation, providing structural insights into the terminal complement pathway activation mechanism.\",\n      \"method\": \"Cryo-electron microscopy, X-ray crystallography (2.7Å), direct C5-CirpT binding assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution structural data with direct binding validation identifying the MG4 domain as functionally important\",\n      \"pmids\": [\"31871188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Ischemic cortical neurons constitutively express C5 and its receptor CD88; oxygen-glucose deprivation increases C5a levels in media and upregulates CD88; exogenous C5a induces neuronal apoptosis via CD88, and CD88 antagonism or CD88-knockout reduces ischemia-induced apoptosis and infarct volume in MCAO stroke model.\",\n      \"method\": \"Primary neuronal cultures, oxygen-glucose deprivation, C5a ELISA, C5aR antagonist (PMX53), CD88-knockout mice, MCAO stroke model, apoptosis assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo complementary methods with KO validation and specific phenotypic readout\",\n      \"pmids\": [\"22651932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"C5b-9 assembles on the basal surface of retinal pigment epithelial cells and is eliminated via dynamin-dependent endocytosis into early endosomes and lysosomes; blocking endocytosis with dynasore retains C5b-9 at the cell surface and causes mitochondrial structural defects consistent with cell stress.\",\n      \"method\": \"Live cell imaging, dynasore inhibition, EEA1 colocalization, lysosomal protease inhibitors, mitochondrial morphology analysis in primary porcine RPE cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct mechanistic dissection of C5b-9 clearance pathway with functional consequence\",\n      \"pmids\": [\"26324770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"C5a activation of C5aR1 on platelets induces preferential release of CXCL4 (PF4) as an antiangiogenic paracrine effector; platelet-specific C5aR1 deletion results in a proangiogenic phenotype with increased collateralization and capillarization; C5a/C5aR1 axis thus negatively regulates tissue neovascularization through CXCL4 release.\",\n      \"method\": \"Platelet-specific C5aR1 knockout mice, in vitro endothelial migration and tube formation assays, Matrigel plug assay, CXCL4 release quantification, vascular morphometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type specific knockout with in vitro and in vivo validation and identification of specific effector molecule\",\n      \"pmids\": [\"34099640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"C5a-C5aR1 signaling promotes fungal clearance in systemic candidiasis by stimulating phagocyte effector function and ERK- and AKT-dependent survival in infected tissues; local C5 produced intrinsically by phagocytes (not only hepatocyte-derived circulating C5) provides the key substrate for antifungal protection.\",\n      \"method\": \"C5ar1 knockout mice, systemic candidiasis model, macrophage survival assays (ERK/AKT pathway), mTOR metabolic pathway analysis, phagocyte-specific C5 expression studies, patient correlation of C5a levels and C5 polymorphism with outcomes\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with mechanistic pathway dissection (ERK/AKT, mTOR) and orthogonal patient data supporting phagocyte-intrinsic C5 function\",\n      \"pmids\": [\"37220746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TLR activation enhances C5a-induced pro-inflammatory responses by downregulating C5L2 activity, which normally acts as a negative modulator of C5aR signaling; TLR-induced hypersensitivity to C5a is mimicked by C5L2 blockade and absent in C5L2-knockout mice.\",\n      \"method\": \"C5L2 knockout mice, TLR ligand pretreatment of PBMCs and whole blood, C5L2 blocking antibody, calcium mobilization assay, cytokine measurements\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockout plus antibody blockade with mechanistic pathway identification across in vitro and in vivo settings\",\n      \"pmids\": [\"21630250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Orai1 is a key Ca²⁺ channel mediating C5a receptor signaling in neutrophils; Orai1-deficient neutrophils show defective C5a-induced Ca²⁺ influx and migration but normal STIM1-dependent SOCE and normal CXCL2 responses; Orai1-deficient chimeric mice show impaired neutrophil recruitment in C5a-dependent inflammation models.\",\n      \"method\": \"Orai1/STIM1 knockout mice, bone marrow chimeras, Ca²⁺ imaging, neutrophil migration assays, LPS peritonitis and hypersensitivity pneumonitis models\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — double knockout comparison (Orai1 vs. STIM1) establishing STIM1-independent Ca²⁺ entry pathway specific to C5aR signaling\",\n      \"pmids\": [\"25912155\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Complement C5 is cleaved by C5 convertases (whose affinity for C5 increases >1000-fold upon additional C3b deposition) or by phagocyte/cancer-cell membrane serine proteases to release C5a (a 74-residue anaphylatoxin) and C5b; C5a signals through the classical G-protein-coupled receptor C5aR1/CD88 (whose N-terminal sulfated tyrosines mediate initial C5a docking and whose phosphorylation/dephosphorylation cycle controls desensitization and recycling) via Gi→Ras→Raf→MEK→ERK and PI3K/Akt pathways to drive neutrophil chemotaxis, phagocyte activation, and inflammatory cytokine release, while the atypical receptor C5aR2 acts as a C5a transporter on endothelial cells and a context-dependent modulator of C5aR1 signaling; C5b sequentially recruits C6 and C7 through its α'-chain to form the membrane-inserting C5b-7 complex, ultimately assembling the C5b-9 membrane attack complex that causes cytolysis or, at sublytic levels, activates ERK and PI3K/Akt to promote cell survival and proliferation; C5a activity is terminated by carboxypeptidase R/N cleavage of C-terminal Arg74 or by PPAD-mediated citrullination of the same residue.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification:**\n\nPapers clearly about complement C5 (the protein): KEEP — papers [1]-[15], [17]-[23], [25]-[35], [37]-[35], [37]-[52], [53]-[57], [60]-[73], [75]-[98], [100]; additional papers [3], [7], [10]-[11], [14], [18], [22]-[25], [28]-[29]\n\nPapers to EXCLUDE:\n- [36]: \"c5 DNA methyltransferases\" — alias collision (C5-MTase/DNMT, not complement C5)\n- [59]: \"C5-methyltransferases\" — same alias collision\n- [74]: \"Hexuronyl C5-epimerases\" — alias collision (C5-epimerase in alginate/GAG biosynthesis)\n- [99]: \"C-5 propyne antisense oligonucleotides\" — alias collision (C-5 propyne modification of nucleotides)\n- Additional [2], [5], [6], [8], [12], [13], [15], [16], [17], [19], [20]: Large-scale genomics/proteomics with no mechanistic content about C5 protein — exclude as not mechanistic\n- Additional [1], [4], [9], [21], [26], [27], [30]: GWAS/association studies — exclude as not mechanistic\n- [58]: lncRNA C5T1lncRNA — alt-locus product (EXCLUDE, case B), though it influences C5 mRNA; the finding is about the lncRNA not C5 protein mechanism\n\nNow extracting mechanistic discoveries from KEPT papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1969,\n      \"finding\": \"A neutrophil chemotactic factor was identified as a fragment derived from complement component C5 (C'5), establishing that C5 cleavage generates a potent leukocyte chemoattractant (C5a).\",\n      \"method\": \"In vitro chemotaxis assay with C5-derived fractions\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational functional characterization, replicated widely across subsequent decades\",\n      \"pmids\": [\"5765461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1978,\n      \"finding\": \"Complete primary structure of human C5a was determined: 74 amino acids with a single complex oligosaccharide at Asn64, three disulfide bonds, and a C-terminal Arg74 critical for chemotactic activity (removal as C5a-desArg reduces leukotaxis).\",\n      \"method\": \"Protein sequencing, carbohydrate analysis, functional chemotaxis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct protein sequencing with functional validation, foundational structure-function study\",\n      \"pmids\": [\"690134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1978,\n      \"finding\": \"C3a and C5a were shown to be chemotactic for human leukocytes in vitro; C5a is substantially more potent than C3a as a leukocyte chemoattractant.\",\n      \"method\": \"In vitro leukotaxis assays; in vivo stimulated conditions\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — replicated foundational functional assay across multiple conditions\",\n      \"pmids\": [\"342601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Limited cleavage of the C5 alpha-chain by non-complement proteases (trypsin, thrombin, plasmin, elastase) generates C5a-like biological activities (neutrophil enzyme release and chemotaxis) without releasing free polypeptide fragments; the cleaved fragments remain disulfide-bonded to the C5 molecule.\",\n      \"method\": \"In vitro proteolysis, SDS-PAGE, gel filtration, neutrophil functional assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with multiple enzymes and orthogonal structural/functional readouts\",\n      \"pmids\": [\"6222137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"The C5a receptor on human PMN was identified by affinity cross-linking with 125I-C5a; the receptor binding moiety has an apparent molecular mass of ~40 kDa (complex ~52 kDa), distinct from nonspecific proteins, and shows specificity for C5a over fMLP and LTB4.\",\n      \"method\": \"Affinity cross-linking with disuccinimidyl suberate, SDS-PAGE, competition binding\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct affinity labeling with rigorous specificity controls\",\n      \"pmids\": [\"3997862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"A three-dimensional model of C5a was built by comparative modeling from the C3a crystal structure, predicting conservation of the 4-helix core while external residues differ; the model suggested a possible receptor-binding site on C5a.\",\n      \"method\": \"Comparative molecular modeling based on C3a crystal structure\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational modeling only, no experimental validation in this paper\",\n      \"pmids\": [\"3992245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"C5b-6 requires negatively charged phospholipids (phosphatidylglycerol or phosphatidic acid) for initial membrane binding; after forming C5b-7, the complex inserts into membranes of all phospholipid compositions with ~20-fold selectivity for small over large unilamellar vesicles. C6 and C7 associate preferentially with the alpha'-chain of C5b.\",\n      \"method\": \"Lipid vesicle binding assays, activation energy measurements, bimolecular kinetics\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted membrane insertion with defined lipid compositions and kinetic characterization\",\n      \"pmids\": [\"3801440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"C5a des-Arg (lacking C-terminal Arg74) retains in vivo inflammatory activity in human skin (wheal-and-flare, neutrophil infiltration, mast cell degranulation) but is less potent than intact C5a, indicating the C-terminal arginine enhances but is not absolutely required for all biological activities.\",\n      \"method\": \"Intradermal injection in human volunteers, histological analysis, in vitro binding\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct human in vivo challenge with purified proteins, histological confirmation\",\n      \"pmids\": [\"3351304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"C5a receptors on human eosinophils display two populations (high-affinity Kd ~31 pM, ~17,500 sites/cell; low-affinity Kd ~100 nM), with a C5a-receptor cross-linked complex of ~60-65 kDa — larger than the neutrophil receptor complex (~52 kDa) — suggesting distinct receptor molecules on eosinophils versus neutrophils.\",\n      \"method\": \"125I-C5a binding (Scatchard analysis), covalent cross-linking with DSS, SDS-PAGE, cyanogen bromide cleavage\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — rigorous receptor pharmacology with direct affinity labeling and structural comparison\",\n      \"pmids\": [\"2912983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Three-dimensional NMR spectroscopy (3D heteronuclear 1H-15N) of uniformly 15N-labeled C5a was demonstrated, providing resonance assignments and distance constraints consistent with a 4-helix bundle core structure and a flexible C-terminus.\",\n      \"method\": \"3D heteronuclear NMR spectroscopy with 15N-labeled recombinant C5a\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct NMR structural characterization with isotope labeling\",\n      \"pmids\": [\"2730871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The human C5a receptor was cloned from U937 and HL-60 cells; expression in COS-7 cells confirmed high-affinity C5a binding. The deduced amino acid sequence revealed seven hydrophobic transmembrane domains, placing C5aR in the G-protein-coupled receptor superfamily.\",\n      \"method\": \"cDNA cloning, heterologous expression in COS-7 cells, radioligand binding\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — direct cloning with functional reconstitution, replicated in multiple cell types\",\n      \"pmids\": [\"1847994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The structure of complement C5b-7 was elucidated: plasmin cleaves C5b's alpha'-chain into C5c (Mr 142,000) and C5d (Mr 43,000); antibodies to C5c block C5b-6 interaction with C7, while antibodies to C5d inhibit C5 binding to C3b; chemical cross-linking showed both C6 and C7 associate preferentially with the alpha'-chain of C5b, and the C-terminal cysteine-rich domains of C6 and C7 bind specifically to C5.\",\n      \"method\": \"Limited proteolysis, circular dichroism, polyclonal antibody blocking, chemical cross-linking, solid-phase binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal structural and functional methods, defined binding domains\",\n      \"pmids\": [\"1387399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Terminal complement complexes C5b-7, C5b-8, and C5b-9 (MAC) generate non-lethal cellular signals including Ca2+ influx and second messengers (cAMP, inositol phosphates, arachidonate metabolites) in a cell-type-specific manner, demonstrating signaling functions of the MAC beyond cytolysis.\",\n      \"method\": \"Cell signaling assays, ion flux measurements, second messenger quantification in specific cell types\",\n      \"journal\": \"Immunologic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling readouts but review-style compilation without single definitive structural experiment\",\n      \"pmids\": [\"8288945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"C5a receptor activation in human neutrophils signals through Gi proteins to activate both B-Raf and Raf-1 (with temporally distinct kinetics), MEK-1, and MAP kinase, as well as Ras (via guanine nucleotide exchange); both PKC-dependent and -independent pathways contribute, and PKA activation inhibits Raf.\",\n      \"method\": \"Kinase activity assays, Ras GTP-loading assay, pertussis toxin (Gi inhibition), PKC modulators, cAMP/PKA manipulation in human neutrophils\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal signaling pathway assays with pharmacological dissection\",\n      \"pmids\": [\"8090790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Site-directed mutagenesis of recombinant human C5a identified 10 non-contiguous charged amino acids in the 4-helix core plus the C-terminal Arg74 as comprising the pharmacophore; Arg74 substitution produced the largest single reduction in receptor binding and Ca2+ mobilization; C3a/C5a hybrid analysis confirmed the two-domain pharmacophore model.\",\n      \"method\": \"Site-directed mutagenesis, receptor binding assay, intracellular Ca2+ mobilization assay\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with multiple functional readouts across the full protein\",\n      \"pmids\": [\"7987211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Mutagenesis of human C5a confirmed that Lys19 and/or Lys20 are critical receptor-interacting residues (>30-fold activity loss on double replacement), while Arg40 and Pro45 replacements had little effect; des-Arg74 C5a retains C5aR activation in Xenopus oocytes but is inactive in the guinea pig ileum assay, revealing species-specific receptor differences.\",\n      \"method\": \"Site-directed mutagenesis, myeloperoxidase-release assay from granulocytes, Xenopus oocyte expression, CD spectroscopy for structural integrity\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — site-directed mutagenesis with structural and functional validation across multiple assay systems\",\n      \"pmids\": [\"8112341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"C5a receptors on C5aR-deficient mice revealed that the C5a receptor is required for non-redundant mucosal host defence; C5aR knockout mice failed to clear Pseudomonas aeruginosa despite increased neutrophil influx, indicating C5aR controls neutrophil effector function rather than merely recruitment.\",\n      \"method\": \"C5aR gene disruption (knockout mice), intrapulmonary bacterial challenge, bacterial clearance assays, neutrophil quantification\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with specific in vivo phenotypic readout\",\n      \"pmids\": [\"8779720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Agonist-occupied C5aR is phosphorylated by a G protein-coupled receptor kinase independently of Gi activation (pertussis toxin-insensitive); receptor dephosphorylation by PP1/PP2A-type phosphatases (okadaic acid-sensitive) is required for recycling of internalized C5aR back to the plasma membrane, suggesting dephosphorylation enables receptor resensitization.\",\n      \"method\": \"32P-phosphorylation assays, pertussis toxin treatment, okadaic acid (phosphatase inhibitor), receptor internalization/recycling kinetics in differentiated HL60 cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — mechanistic dissection of receptor phosphorylation/dephosphorylation cycle with pharmacological tools\",\n      \"pmids\": [\"7706744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"C3a and C5a are chemotactic factors for human mast cells (HMC-1 line, cord blood-derived mast cells, cutaneous mast cells); migration requires extracellular matrix (laminin), is dose-dependent, inhibited by specific antibodies, and blocked by pertussis toxin indicating Gi protein coupling; both anaphylatoxins also mobilize intracellular Ca2+ in mast cells.\",\n      \"method\": \"Chemotaxis assays on laminin matrix, pertussis toxin treatment, calcium imaging with Fura-2\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including signaling readouts and pharmacological inhibition across multiple human mast cell types\",\n      \"pmids\": [\"9108406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In renal ischemia/reperfusion injury, C5-deficient and C6-deficient (but not C4-deficient) mice are protected, and C6-deficient mice treated with anti-C5a showed no additional protection; reconstitution of C6 alone restored injury in C6-deficient mice. This demonstrates that the membrane attack complex (C5b-9, requiring both C5 and C6) rather than C5a-mediated neutrophil infiltration is the predominant mediator of renal I/R injury.\",\n      \"method\": \"Complement-deficient mouse models, renal artery occlusion model, histology, functional assays, antibody neutralization, reconstitution experiments\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with reconstitution experiment across multiple complement-deficient strains\",\n      \"pmids\": [\"10811844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Sublytic C5b-9 (MAC) activates the cell cycle and promotes cell survival via Gi-mediated ERK1/2 activation and PI3K/Akt pathway, which inhibits apoptosis through regulation of BAD; C5b-9 also reverses differentiated phenotype of postmitotic cells such as oligodendrocytes.\",\n      \"method\": \"Cell cycle analysis, kinase activity assays (ERK, PI3K/Akt), apoptosis assays, differentiation markers\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple signaling readouts but review compilation of prior work\",\n      \"pmids\": [\"11414362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Tyrosines at positions 11 and 14 of the C5aR N-terminal domain are post-translationally sulfated; these sulfate moieties are critical for C5a binding and Ca2+ mobilization. A C5aR variant lacking sulfation responds normally to a small peptide agonist but not to intact C5a, supporting a two-site model where the sulfated N-terminus mediates the initial docking interaction with C5a.\",\n      \"method\": \"Post-translational modification analysis, site-directed mutagenesis, 35S-sulfate labeling, Ca2+ mobilization assay, peptide inhibition assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — identification of specific PTM with mutagenesis, isotope labeling, and multiple functional assays supporting two-site docking model\",\n      \"pmids\": [\"11342590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Rainbow trout C5 (first non-human/mouse C5 cloning) shows ~60% similarity to human C5, is expressed as a single gene in liver, confirming evolutionary conservation of C5 structure and hepatic expression across vertebrates.\",\n      \"method\": \"cDNA library cloning, Northern blot, Southern blot, mass spectrometry of tryptic digests, protein purification\",\n      \"journal\": \"Developmental and comparative immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct molecular cloning with protein-level validation by mass spectrometry\",\n      \"pmids\": [\"11356221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Sublytic C5b-9 induces ERK activation in glomerular epithelial cells via Ras and, in part, PKC-dependent pathways; this ERK activation depends on actin cytoskeletal integrity (blocked by cytochalasin D and latrunculin B) and is attenuated by constitutively active RhoA and ROCK inhibition; ERK activation leads to phosphorylation of cytosolic PLA2 and MAPKAPK-2 but not Elk-1, and is functionally distinct from the cytotoxic pathway.\",\n      \"method\": \"Dominant-negative Ras, pharmacological inhibitors (cytochalasin D, latrunculin B, ROCK inhibitor), constitutively active RhoA overexpression, kinase phosphorylation assays\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple orthogonal genetic and pharmacological tools dissecting pathway components\",\n      \"pmids\": [\"15855657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"C5 convertase specificity is regulated by C3b deposition density: monomeric C3b-containing convertases have a Km for C5 of ~25 µM (poor C5 cleavage); deposition of additional C3b on cell surfaces creates C3b-C3b and C4b-C3b complexes that shift Km for C5 more than 1000-fold (below physiological C5 concentration), switching the enzyme from C3 to C5 cleavage and initiating MAC formation.\",\n      \"method\": \"In vitro enzyme kinetics (Km determination), cell surface complement activation assays, convertase assembly reconstitution\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative enzyme kinetics with reconstituted convertase showing >1000-fold Km shift\",\n      \"pmids\": [\"12440962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Activated phagocytic cells (neutrophils and alveolar macrophages) generate biologically active C5a from exogenous C5 via a serine protease-dependent mechanism that is sensitive to transcription/translation inhibitors in macrophages but only partially in neutrophils, indicating a novel complement-independent pathway for C5a generation by phagocytes.\",\n      \"method\": \"Incubation of phagocytes with C5, antibody detection of C5a, serine protease inhibitors (aprotinin), actinomycin D/cycloheximide treatment, chemotaxis bioassay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — direct demonstration of cell-mediated C5 cleavage with serine protease inhibition and transcription inhibitor controls\",\n      \"pmids\": [\"12414531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Carboxypeptidase R (thrombin-activatable fibrinolysis inhibitor, TAFI) cleaves the C-terminal Arg from C5a much more efficiently than the classical carboxypeptidase N, inactivating the anaphylatoxin; upregulation of proCPR in inflammatory states suggests CPR is a major physiological inactivator of C5a.\",\n      \"method\": \"In vitro enzyme assay with C5a octapeptide substrate, kinetic comparison of CPR versus CPN activity\",\n      \"journal\": \"Microbiology and immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay comparing two carboxypeptidases on C5a substrate\",\n      \"pmids\": [\"11939578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C5L2 (GPR77/C5aR2) is a high-affinity C5a binding protein that is obligately uncoupled from heterotrimeric G proteins due to a Leu-for-Arg substitution in the DRY sequence at the end of transmembrane segment 3; it shows weak phosphorylation, no MAP kinase activation, no Ca2+ flux, and no chemotaxis induction upon C5a binding, and it does not interact with C3a or C4a.\",\n      \"method\": \"Radioligand binding, G-protein coupling assays (cAMP, calcium flux), MAP kinase assays, phosphorylation assays, chemotaxis assay, microarray analysis of C5aR-KO vs. C5L2-only cells, sequence analysis of DRY motif\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — comprehensive pharmacological and biochemical characterization with mechanistic identification of DRY motif alteration\",\n      \"pmids\": [\"12899627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"C3a and C5a anaphylatoxins are essential for liver regeneration: C3- or C5-deficient mice show high mortality and impaired regeneration after partial hepatectomy; combined deficiency is rescued by reconstitution with both C3a and C5a; C5aR signaling is required for IL-6/TNFα induction and NF-κB/STAT-3 activation in the early priming phase of hepatocyte proliferation.\",\n      \"method\": \"Complement-deficient mouse models, partial hepatectomy, cytokine ELISA, NF-κB/STAT-3 activation assays, reconstitution with recombinant C3a/C5a\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with rescue reconstitution and defined signaling pathway readouts\",\n      \"pmids\": [\"12975457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Complement factor C5 (encoded by the Hc gene) was identified as the quantitative trait gene underlying a hepatic fibrosis susceptibility locus; small molecule C5aR antagonists had antifibrotic effects in vivo, and common C5 haplotype polymorphisms associated with advanced fibrosis in human hepatitis C, establishing C5/C5a-C5aR as a causal pathway in fibrogenesis.\",\n      \"method\": \"In silico QTL mapping, congenic mice, transgenesis with recombined artificial chromosomes (BAC/YAC), C5aR antagonist treatment, human genetic association\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — genetic causality established by transgenesis/congenic mapping with in vivo pharmacological validation\",\n      \"pmids\": [\"15995705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"C3a and C5a generated in drusen induce VEGF expression in retinal pigmented epithelium in vitro and in vivo; genetic ablation of C3aR or C5aR reduces VEGF, leukocyte recruitment, and choroidal neovascularization after laser injury, establishing C5a-C5aR signaling as a mechanistic link between complement activation and angiogenesis in AMD.\",\n      \"method\": \"VEGF ELISA from C5a/C3a-stimulated cells, C3aR/C5aR knockout mice, laser-induced CNV model, leukocyte recruitment quantification, antibody neutralization, pharmacological receptor blockade\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus antibody neutralization plus pharmacological blockade converging on same mechanistic conclusion\",\n      \"pmids\": [\"16452172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"C5L2 (GPR77) facilitates C5a signaling in neutrophils, macrophages, and fibroblasts in vitro and is required for optimal C5a-mediated inflammatory cell infiltration in vivo; C5L2-deficient mice are hypersensitive to LPS-induced septic shock, show reduced OVA-induced airway hyper-responsiveness, and are mildly delayed in hematopoietic regeneration after irradiation — phenotypes mirroring C3aR-deficient mice.\",\n      \"method\": \"Gene targeting (C5L2 KO mice), in vitro signaling assays in primary cells, in vivo LPS sepsis model, OVA airway inflammation model, gamma-irradiation hematopoiesis recovery\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with multiple orthogonal in vivo and in vitro readouts\",\n      \"pmids\": [\"17322907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"C5ar (C5aR1) and C5l2 (C5aR2/GPR77) contribute synergistically to harmful outcomes in sepsis; C5l2 specifically is required for in vivo and in vitro release of HMGB1 in a C5ar-independent manner; combined blockade of both receptors is required for protection in high-grade sepsis.\",\n      \"method\": \"Cecal ligation and puncture (CLP) model, receptor knockout mice, anti-receptor antibody blockade, HMGB1 ELISA, cytokine profiling\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dual genetic KO and antibody blockade with specific mechanistic readout (HMGB1 release)\",\n      \"pmids\": [\"18454156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"C5a and C5a-desArg signal through C5aR on dorsal root ganglia neurons to induce Ca2+ influx and sensitize C-nociceptors to heat; C5a sensitizes heat-responsive C-fibers (lower threshold, more action potentials) and activates A-nociceptors; C5aR mRNA is expressed in DRG.\",\n      \"method\": \"In vivo intraplantar injection, in vitro skin-nerve preparation, Ca2+ imaging (Fura-2), RT-PCR for C5aR mRNA in DRG\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct C-fiber electrophysiology combined with Ca2+ imaging and in vivo behavioral validation\",\n      \"pmids\": [\"20031321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Ischemic cortical neurons constitutively express C5 (the C5a precursor) and CD88 (C5aR); glucose deprivation or OGD increases C5a levels in culture media and upregulates CD88; exogenous C5a induces neuronal apoptosis; PMX53 (CD88 antagonist) or CD88 knockout reduces ischemia-induced apoptosis ~50%; CD88-KO mice have reduced infarct volumes after MCAO, demonstrating a local autocrine/paracrine C5a-CD88 apoptotic signaling loop in neurons.\",\n      \"method\": \"Primary neuronal culture, oxygen-glucose deprivation, C5a ELISA, CD88 antagonist (PMX53), CD88-KO mice, MCAO stroke model, infarct volume measurement\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo genetic/pharmacological evidence converging on a defined apoptotic mechanism\",\n      \"pmids\": [\"22651932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"C5a promotes migration, proliferation, and 3D tube/ring formation of human microvascular endothelial cells (HMEC-1) in a dose-dependent manner via C5aR; C5aR antagonist W-54011 suppresses all these activities; Matrigel plug assay confirms pro-angiogenic effect in vivo.\",\n      \"method\": \"Cell cycle/proliferation assays (BrdU/FACS), Chemotaxicell migration assay, collagen gel ring formation, Matrigel plug in vivo, C5aR antagonist W-54011\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro functional assays with receptor-specific pharmacological inhibition and in vivo confirmation\",\n      \"pmids\": [\"20217457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"C5a selectively induces migration of STRO-1+/C5aR+ pulp progenitor cells via C5aR; perivascular localization of these progenitor cells was confirmed; C5aR antagonist W54011 blocks C5a-induced progenitor migration, and C5b-9 is detected in carious teeth, suggesting complement activation generates a C5a gradient that guides stem cell recruitment for dentin regeneration.\",\n      \"method\": \"Immunofluorescence, RT-PCR on STRO-1-sorted cells, C5aR antagonist-blocked migration assays, immunohistochemistry for C5b-9\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — receptor antagonist migration assay in primary cells with localization data; single lab\",\n      \"pmids\": [\"23603337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lung cancer cells constitutively produce C5a from C5 via a membrane-bound serine protease (sensitive to aprotinin and a furin-like inhibitor but not cysteine, acid, or metalloprotease inhibitors); this C5a acts on C5aR-expressing cancer cells to enhance invasion in vitro.\",\n      \"method\": \"C5a ELISA from conditioned media, serine protease inhibitor panel (aprotinin, RVKR-cmk), invasion assay, anti-C5a antibody neutralization\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with protease inhibitor panel and neutralizing antibody, single lab\",\n      \"pmids\": [\"25050844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A heterozygous C5 missense mutation p.Arg885His (c.2654G→A), present in ~3.2% of Japanese and Han Chinese individuals, generates functionally active C5 that causes hemolysis normally but fails to bind eculizumab; this variant accounts for poor response to eculizumab in PNH patients. A second binding antibody (N19-8) targeting a different C5 epitope blocks both wild-type and mutant C5.\",\n      \"method\": \"Gene sequencing, in vitro hemolysis assay with mutant C5, eculizumab binding assay, N19-8 antibody blocking assay\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — direct functional characterization of variant protein with antibody binding assays and hemolysis reconstitution\",\n      \"pmids\": [\"24521109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Porphyromonas gingivalis peptidylarginine deiminase (PPAD) citrullinates the critical C-terminal Arg74 of C5a, disabling its function: citrullinated C5a shows diminished neutrophil chemotaxis and reduced Ca2+ signaling via C5aR; P. gingivalis outer membrane vesicles generate fully citrullinated C5a (Arg74Cit) while PPAD-null vesicles do not.\",\n      \"method\": \"In vitro PPAD treatment of C5a, neutrophil chemotaxis assay, Ca2+ imaging (Fura-2 AM) in U937/C5aR cells, mass spectrometry (citrullination mapping), outer membrane vesicle treatment of C5\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic modification with mass spectrometric site identification and multiple functional readouts\",\n      \"pmids\": [\"25324545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Neutrophil-derived phosphatidylserine-positive microvesicles suppress C5a-mediated priming of the NLRP3 inflammasome (reducing IL-1β release and neutrophil influx) via the PS-receptor MerTK; in a murine MSU peritonitis model, C5a generated after MSU injection primes the inflammasome, and PMN-derived ectosomes (generated in response to C5a) act as a negative-feedback autoregulatory loop requiring C5aR on resident cells.\",\n      \"method\": \"C5aR-KO mice, MerTK-KO mice, MSU peritonitis model, IL-1β ELISA, PS-liposome functional mimics, human joint aspirate ectosomes\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO mouse models with mechanistic reconstitution using PS liposomes\",\n      \"pmids\": [\"26245757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Three crystal structures of C5 in complex with distinct tick-derived inhibitors (OmCI, a second OmCI-class inhibitor, and eculizumab Fab) reveal three non-overlapping binding sites on C5 that all prevent its activation by C5 convertases; all three complexes competitively inhibit the C5 convertase, inconsistent with simple steric blockade and suggesting a priming/conformational event is required for C5 activation.\",\n      \"method\": \"X-ray crystallography of C5-inhibitor complexes, cryo-EM, competitive inhibition assays of C5 convertase\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple crystal structures with functional convertase inhibition assays; mechanistic model supported by structural comparison\",\n      \"pmids\": [\"27018802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Two crystal structures of human C5aR in ternary complexes reveal orthosteric action of the peptide antagonist PMX53 (stabilizing the C5aR structure) and allosteric binding of non-peptide antagonists (avacopan and NDT9513727) at a distinct intracellular allosteric site with different binding poses; helix 8 adopts a novel conformation relevant to C5aR activation.\",\n      \"method\": \"X-ray crystallography of C5aR ternary complexes, computational docking, biophysical binding assays, cell-based signaling assays\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with multiple orthogonal validation methods defining orthosteric and allosteric sites\",\n      \"pmids\": [\"29867214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"C5aR2 (the 'atypical' C5a receptor) expressed on endothelial cells transports C5a from tissue into the vessel lumen via a transcytosis-like mechanism (intravital microscopy); this transported C5a is required to initiate C5aR1-mediated neutrophil arrest, while ACKR1 transports chemokines for CXCR2-dependent transendothelial migration — defining distinct roles for the two transport receptors in sequential steps of neutrophil recruitment.\",\n      \"method\": \"Intravital microscopy in live mice, immune complex arthritis model, C5aR2-KO and ACKR1-KO mice, fluorescent C5a tracking\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — intravital microscopy with genetic KO models demonstrating transcytotic transport mechanism in vivo\",\n      \"pmids\": [\"31076525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"C5aR2 physically interacts with C5aR1 and β-arrestin to negatively modulate C5aR1 signaling; in an MPO-ANCA GN model, C5aR2 deficiency worsens disease while C5aR1 deficiency ameliorates it, demonstrating that C5aR1 engagement enhances inflammation and C5aR2 engagement suppresses inflammation in the same in vivo context.\",\n      \"method\": \"C5aR2-KO, C5aR1-KO, and human C5aR knock-in mice; MPO-ANCA GN model; CCX168 (C5aR1 antagonist) oral administration; co-immunoprecipitation of C5aR2-C5aR1-β-arrestin complex\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological evidence with Co-IP demonstrating physical C5aR1/C5aR2/β-arrestin interaction\",\n      \"pmids\": [\"24179165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A CirpT inhibitor from tick saliva binds directly to the peripheral MG4 domain of C5 (solved by cryo-EM at the full-C5 level and X-ray crystallography of C5_MG4-CirpT at 2.7 Å); this interaction prevents C5 activation by competitively inhibiting the C5 convertase, providing structural evidence that the MG4 domain is functionally important for convertase-mediated C5 activation.\",\n      \"method\": \"Cryo-electron microscopy (C5-CirpT complex), X-ray crystallography (C5_MG4-CirpT at 2.7 Å), direct binding assays, convertase inhibition assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM and crystal structure with functional convertase inhibition validation\",\n      \"pmids\": [\"31871188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"C5a-C5aR1 activation on platelets induces preferential release of CXCL4 (PF4), an antiangiogenic factor; platelet-specific C5aR1 deletion produces a proangiogenic phenotype with increased collateralization and capillarization; growth factor- and hypoxia-driven vascularization is markedly increased in global C5ar1-/- mice; interfering with the C5aR1-CXCL4 axis reverses the antiangiogenic platelet effect in vitro and in vivo.\",\n      \"method\": \"Platelet-specific C5aR1 KO mice, global C5ar1-/- mice, CXCL4 ELISA from C5a-stimulated platelets, endothelial cell migration/tube formation assays, in vivo angiogenesis models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — platelet-specific and global KO models with defined molecular effector (CXCL4) and in vitro/in vivo confirmation\",\n      \"pmids\": [\"34099640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"C5a-C5aR1 signaling promotes fungal clearance and host survival in systemic candidiasis by stimulating phagocyte effector function and ERK- and AKT-dependent phagocyte survival in infected tissues; C5ar1 ablation rewires macrophage metabolism downstream of mTOR, promoting macrophage apoptosis. Critically, local C5 produced intrinsically by phagocytes (not only hepatocyte-derived C5) provides a key substrate for antifungal protection.\",\n      \"method\": \"C5ar1-KO mice, Candida infection model, RNA-seq, metabolomics, mTOR pathway inhibitors, phagocyte-specific C5 expression analysis, patient cohort correlation of C5a levels with outcome\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with mechanistic dissection of ERK/AKT/mTOR pathway and identification of phagocyte-intrinsic C5 production as key substrate source\",\n      \"pmids\": [\"37220746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Complement C5 is the molecular basis of the hepatic fibrosis susceptibility QTL (Hc locus): congenic mice and BAC transgenesis with the Hc gene confirmed that C5 underlies fibrosis susceptibility; C5aR antagonist treatment had antifibrotic effects, linking C5 cleavage to C5a-C5aR-mediated fibrogenesis.\",\n      \"method\": \"Congenic mouse mapping, BAC transgenesis, C5aR antagonist in vivo treatment, liver fibrosis quantification\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — genetic causality established by transgenesis with in vivo pharmacological validation\",\n      \"pmids\": [\"15995705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"C5a anaphylatoxin regulates the activating/inhibitory FcγR balance on alveolar macrophages: C5a upregulates FcγRIII (activating) and downregulates FcγRII (inhibitory) via C5aR signaling; this bidirectional modulation is required for efficient cytokine production and neutrophil recruitment in immune complex-induced lung disease, connecting C5a to FcγR-complement crosstalk.\",\n      \"method\": \"FcγR expression by flow cytometry on alveolar macrophages, recombinant C5a stimulation, C5aR-KO and FcγRIII-KO mice, immune complex pulmonary model, cytokine ELISA\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO models with in vitro and in vivo mechanistic readouts, specific receptor-pathway linkage\",\n      \"pmids\": [\"12488432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CFHR1 (Factor H-related protein 1) inhibits complement C5 convertase activity and C5b surface deposition and MAC formation through a mechanism distinct from factor H (which inhibits C3 convertase); CFHR1 and factor H bind overlapping surface sites, suggesting sequential control of complement activation — factor H limits C3 convertase, CFHR1 limits C5 convertase/terminal pathway.\",\n      \"method\": \"C5 convertase activity assay (inhibition by CFHR1), C5b and MAC deposition assays on cell surfaces, competition binding with factor H\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — direct in vitro enzymatic inhibition assays defining a novel regulatory mechanism\",\n      \"pmids\": [\"19528535\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Complement C5 is cleaved at its alpha-chain by C5 convertases (whose C5-specificity is allosterically triggered by C3b density), as well as by non-complement serine proteases from phagocytes and cancer cells, to release the 74-amino acid anaphylatoxin C5a (whose C-terminal Arg74 and core residues Lys19/20 are critical pharmacophore elements) and C5b; C5a signals primarily through the sulfated-tyrosine N-terminal docking site of C5aR1 (a Gi-coupled GPCR activating Ras/Raf/MEK/ERK and PI3K/Akt), is inactivated by carboxypeptidase R/N, and is modulated by C5aR2 which acts as a transport receptor on endothelium and a negative regulator of C5aR1 via physical interaction with β-arrestin; C5b sequentially recruits C6 (via alpha'-chain interactions), then C7 (via cysteine-rich C6/C7 domains), and inserts into membranes to form the lytic and signaling-competent MAC (C5b-9), whose sublytic form activates ERK, PI3K/Akt, and cell cycle entry; three structurally distinct inhibitor-binding sites on C5 all block convertase-mediated activation, implying a required conformational priming event.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"Complement C5 is the central substrate of the terminal complement cascade, generating two effector arms — the anaphylatoxin C5a and the membrane attack complex (MAC/C5b-9) — that together orchestrate innate immune defense, inflammation, and tissue injury. C5 is cleaved by C5 convertases whose affinity increases >1000-fold upon surface C3b deposition [PMID:12440962], and also by non-complement serine proteases on phagocytes and cancer cells [PMID:6222137, PMID:12414531, PMID:25050844]; the released C5a signals through the GPCR C5aR1/CD88 via Gi→Ras→Raf→MEK→ERK and PI3K/Akt pathways to drive neutrophil chemotaxis, phagocyte bactericidal activity, and inflammatory cytokine release, while C5a is inactivated by carboxypeptidase R removal or bacterial citrullination of C-terminal Arg74 [PMID:8090790, PMID:11939578, PMID:25324545]. C5b initiates MAC assembly by recruiting C6 and C7 through its α'-chain [PMID:1387399]; sublytic C5b-9 on nucleated cells activates ERK and PI3K/Akt to promote cell survival and proliferation, and is cleared by dynamin-dependent endocytosis [PMID:15855657, PMID:11414362, PMID:26324770]. The atypical receptor C5aR2/C5L2 modulates C5a responses in a context-dependent manner, functioning as a C5a transporter on endothelial cells and as a negative or positive modulator of C5aR1 signaling depending on the inflammatory setting [PMID:31076525, PMID:21630250, PMID:17322907].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Establishing that non-complement serine proteases can activate C5 without releasing free C5a resolved whether complement convertases are the sole C5 activators and revealed an alternative mechanism generating C5a-like activity through limited α-chain cleavage.\",\n      \"evidence\": \"In vitro proteolysis of purified C5 with trypsin, thrombin, plasmin, and elastase followed by SDS-PAGE and functional chemotaxis assays\",\n      \"pmids\": [\"6222137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the physiological non-complement protease(s) responsible in vivo was not determined\", \"Stoichiometry and regulation of alternative C5 cleavage in inflammatory settings remained undefined\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Biochemical identification of the C5a receptor on neutrophils as a ~40 kDa specific binding moiety established that C5a acts through a dedicated cell-surface receptor distinct from other chemoattractant receptors.\",\n      \"evidence\": \"Affinity cross-linking of 125I-C5a to PMNs with SDS-PAGE resolution and competition binding\",\n      \"pmids\": [\"3997862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor sequence and signaling mechanism remained unknown\", \"Whether eosinophil and neutrophil receptors were identical proteins was unresolved\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Discovery that eosinophils express two distinct C5a receptor populations (high- and low-affinity) with different molecular weights than the neutrophil receptor raised the question of whether multiple C5a receptor genes or post-translational modifications account for cell-type-specific responses.\",\n      \"evidence\": \"Scatchard analysis and covalent cross-linking on human eosinophils vs. neutrophils\",\n      \"pmids\": [\"2912983\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the two eosinophil receptor populations was not resolved\", \"Functional consequence of dual receptor populations for eosinophil biology was not tested\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Molecular cloning of C5aR/CD88 as a seven-transmembrane GPCR transformed the field by enabling molecular dissection of C5a signaling, receptor mutagenesis, and targeted drug design.\",\n      \"evidence\": \"cDNA cloning from U937/HL-60 cells, heterologous expression in COS-7, radioligand binding confirmation\",\n      \"pmids\": [\"1847994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathways not yet mapped\", \"Receptor regulatory mechanisms (phosphorylation, desensitization) not defined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Mapping the C5b interaction with C6 and C7 to the α'-chain of C5b, and C5–C3b binding to the C5d fragment, defined the molecular architecture underlying MAC assembly initiation.\",\n      \"evidence\": \"Limited proteolysis, cross-linking, solid-phase binding, and antibody blocking of purified complement components\",\n      \"pmids\": [\"1387399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of the C5b–C6–C7 complex was not available\", \"How conformational change upon C5 cleavage exposes the α'-chain binding site was not resolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Dissection of the C5a pharmacophore through systematic mutagenesis identified C-terminal Arg74 and core helix charged residues as critical for receptor binding, and separately showed that C5aR signals through Gi→Ras→Raf→MEK→MAPK, establishing both the ligand determinants and the intracellular cascade.\",\n      \"evidence\": \"Site-directed mutagenesis with binding/calcium assays for C5a; pertussis toxin, kinase activity assays, and PKC/PKA modulation in neutrophils for signaling\",\n      \"pmids\": [\"7987211\", \"8112341\", \"8090790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full three-dimensional structure of C5a–C5aR complex not yet available\", \"Whether Ras–Raf–MEK pathway mediates chemotaxis specifically or broader effector functions was unclear\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating that GRK-mediated phosphorylation and PP1/PP2A-mediated dephosphorylation control C5aR desensitization and recycling defined the regulatory cycle governing receptor responsiveness.\",\n      \"evidence\": \"32P-phosphate incorporation, okadaic acid inhibition, and receptor recycling assays in differentiated HL60 cells\",\n      \"pmids\": [\"7706744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific GRK isoform(s) responsible not identified\", \"Role of β-arrestins in C5aR internalization not addressed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"C5aR knockout mice failing to clear pulmonary Pseudomonas despite adequate neutrophil recruitment established that C5aR has a non-redundant role in neutrophil effector function beyond chemotaxis.\",\n      \"evidence\": \"C5aR-deficient mice challenged with intrapulmonary P. aeruginosa; survival, bacterial burden, and neutrophil counts measured\",\n      \"pmids\": [\"8779720\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific neutrophil effector mechanism (oxidative burst, degranulation) is C5aR-dependent was not dissected\", \"Whether other complement receptors partially compensate was not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Genetic epistasis experiments separating C5a from C5b-9 effector functions in renal ischemia/reperfusion showed that MAC (C5b-9), not C5a-dependent inflammation, is the primary tissue injury effector, resolving a longstanding ambiguity about which C5 cleavage product mediates organ damage.\",\n      \"evidence\": \"C5-, C6-, and C4-deficient mice with renal artery occlusion; C6 reconstitution and anti-C5a blockade\",\n      \"pmids\": [\"10811844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this hierarchy applies to other ischemic organs was not tested\", \"Sublytic MAC signaling contribution to injury vs. direct cytolysis was not separated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of sulfated tyrosines at positions 11 and 14 of the C5aR N-terminus as essential for C5a docking established a two-site binding model and revealed a post-translational modification critical for receptor function.\",\n      \"evidence\": \"Site-directed mutagenesis of Tyr11/Tyr14, calcium mobilization and peptide inhibition assays\",\n      \"pmids\": [\"11342590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how sulfated tyrosines contact C5a was not resolved at atomic level\", \"Whether sulfation varies across cell types was not examined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Three advances converged to refine understanding of C5 activation and C5a inactivation: quantitative kinetics showed C5 convertase affinity for C5 increases >1000-fold with additional C3b, phagocyte-derived serine proteases were confirmed as alternative C5 cleavage enzymes, and carboxypeptidase R was identified as the major C5a inactivator.\",\n      \"evidence\": \"Reconstituted convertase kinetics; C5a generation assays with protease/translation inhibitors; in vitro CPR vs. CPN comparison\",\n      \"pmids\": [\"12440962\", \"12414531\", \"11939578\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific phagocyte serine protease identity remained unknown\", \"In vivo relative contributions of CPR vs. CPN to C5a clearance were not quantified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Characterization of C5L2/GPR77 as a high-affinity C5a-binding GPCR obligately uncoupled from G proteins (due to a DRY→DLC motif change), together with the demonstration that C5a/C5aR drives liver regeneration through NF-κB/STAT3, expanded the C5a signaling framework beyond inflammation.\",\n      \"evidence\": \"C5L2 heterologous expression with binding/signaling assays; C3/C5 knockout mice with hepatectomy and C5a reconstitution\",\n      \"pmids\": [\"12899627\", \"12975457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C5L2 physiological function (decoy vs. signaling vs. transport) was contested\", \"How C5a reaches hepatic stellate/Kupffer cells to trigger regeneration was not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapping sublytic C5b-9 signaling in glomerular epithelial cells to Ras-dependent, PKC-independent ERK activation that requires actin cytoskeleton integrity and is modulated by RhoA/ROCK defined a non-lytic MAC signaling axis distinct from classical complement cytolysis.\",\n      \"evidence\": \"Dominant-negative Ras, actin disassembly drugs, RhoA/ROCK modulation with kinase phosphorylation assays\",\n      \"pmids\": [\"15855657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MAC on the membrane surface communicates to Ras was not identified\", \"Whether this pathway operates in cell types beyond glomerular epithelium was untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"C5L2 knockout mice revealed that C5L2 facilitates rather than inhibits C5a signaling in neutrophils and macrophages, contradicting the initial decoy receptor model and establishing C5L2 as a context-dependent co-receptor.\",\n      \"evidence\": \"C5L2 gene-targeted mice with in vitro signaling assays and in vivo sepsis, asthma, and hematopoietic models\",\n      \"pmids\": [\"17322907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which C5L2 facilitates C5aR1 signaling was not defined\", \"Contradicted by later studies showing negative modulation in other contexts\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"In sepsis, C5L2 was shown to drive HMGB1 release independently of C5aR1, and combined C5aR1/C5L2 blockade was uniquely protective, demonstrating non-redundant and synergistic roles for the two C5a receptors in lethal inflammation.\",\n      \"evidence\": \"C5aR/C5L2 knockout mice and antibody blockade in CLP sepsis model with HMGB1 quantification\",\n      \"pmids\": [\"18454156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway from C5L2 to HMGB1 release was not identified\", \"Whether C5L2-HMGB1 axis operates outside sepsis was unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"TLR activation was shown to sensitize cells to C5a by downregulating C5L2, which normally restrains C5aR1 signaling, providing a mechanistic link between pathogen detection and complement amplification.\",\n      \"evidence\": \"C5L2 knockout mice and blocking antibody with TLR ligand pretreatment of PBMCs; calcium and cytokine readouts\",\n      \"pmids\": [\"21630250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TLR-driven C5L2 downregulation is transcriptional or post-translational was not resolved\", \"Relative importance in different tissue microenvironments not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstration that ischemic neurons constitutively express C5 and CD88, and that neuronal C5a–CD88 autocrine signaling drives apoptosis, extended C5a function beyond leukocyte biology to neuronal cell death.\",\n      \"evidence\": \"Primary neuronal cultures under OGD, C5a ELISA, CD88 antagonist PMX53, CD88-KO mice in MCAO stroke model\",\n      \"pmids\": [\"22651932\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether neuronal C5 cleavage requires convertases or alternative proteases was not determined\", \"Downstream apoptotic pathway downstream of CD88 in neurons not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Three findings refined C5 biology: cancer cell membrane serine proteases were identified as C5a generators promoting invasion; PPAD citrullination of Arg74 was established as a bacterial immune evasion strategy; and the Arg885 polymorphism explained eculizumab treatment failure while remaining hemolytically active.\",\n      \"evidence\": \"Cancer cell C5a assays with inhibitor profiling; PPAD treatment with mass spectrometry and chemotaxis; C5 sequencing with hemolysis and antibody binding assays\",\n      \"pmids\": [\"25050844\", \"25324545\", \"24521109\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the cancer cell serine protease not determined\", \"Prevalence of C5 Arg885 variants across populations not fully characterized\", \"Whether PPAD-citrullinated C5a retains any C5aR2 binding was not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of Orai1 as a STIM1-independent Ca²⁺ channel specific to C5aR signaling in neutrophils, and demonstration that C5b-9 is cleared by dynamin-dependent endocytosis on RPE cells, added new mechanistic details to both C5a receptor signaling and MAC handling by nucleated cells.\",\n      \"evidence\": \"Orai1/STIM1 KO mice with Ca²⁺ imaging and inflammation models; live imaging with dynasore inhibition on RPE cells\",\n      \"pmids\": [\"25912155\", \"26324770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Orai1 is activated independently of STIM1 in response to C5a was not resolved\", \"Whether dynamin-dependent MAC endocytosis operates in all nucleated cell types was not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Crystal and cryo-EM structures of C5 with tick inhibitors and eculizumab Fab revealed three distinct inhibitory binding sites and suggested that a priming conformational change is required for convertase-mediated C5 activation, challenging simple steric-blockade models.\",\n      \"evidence\": \"X-ray crystallography and cryo-EM of C5–inhibitor complexes with competitive convertase assays\",\n      \"pmids\": [\"27018802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of the conformational priming event was not structurally resolved\", \"Structure of C5 bound to an actual C5 convertase was not obtained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Crystal structures of C5aR1 with orthosteric and allosteric antagonists defined both the C5a binding pocket and a novel helix 8 conformation relevant to activation, providing a structural framework for drug design.\",\n      \"evidence\": \"X-ray crystallography of C5aR1-PMX53 and C5aR1-avacopan/NDT complexes with cell-based signaling assays\",\n      \"pmids\": [\"29867214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state C5aR1 structure with bound C5a was not obtained\", \"How helix 8 conformational change translates to G protein coupling was not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Intravital imaging demonstrated that endothelial C5aR2 functions as a transcytosis receptor that transports C5a from tissue to the vascular lumen, resolving the longstanding debate about C5L2 function by identifying a transport role distinct from direct signaling or decoy activity.\",\n      \"evidence\": \"Intravital microscopy in C5aR2-KO mice during immune complex arthritis with C5a tracking\",\n      \"pmids\": [\"31076525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of C5aR2-mediated transcytosis (vesicular trafficking machinery) not defined\", \"Whether C5aR2 transport function extends to other tissues and inflammatory contexts was not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"CryoEM/crystal structure of C5 with CirpT identified macroglobulin domain 4 (MG4) as a functionally important peripheral domain whose engagement blocks C5 activation, adding another inhibitory site to the emerging structural map.\",\n      \"evidence\": \"Cryo-EM and 2.7 Å X-ray crystallography of C5-CirpT and C5_MG4-CirpT complexes\",\n      \"pmids\": [\"31871188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MG4 engagement prevents the priming conformational change was not mechanistically resolved\", \"Relationship between MG4 and convertase binding site not fully clarified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Platelet-specific C5aR1 deletion revealed that C5a–C5aR1 signaling on platelets selectively releases CXCL4 to inhibit angiogenesis, uncovering a non-immune effector function for C5a beyond leukocyte activation.\",\n      \"evidence\": \"Platelet-specific C5aR1 KO mice, in vitro endothelial assays, Matrigel plugs, CXCL4 quantification\",\n      \"pmids\": [\"34099640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway from platelet C5aR1 to selective CXCL4 degranulation was not mapped\", \"Whether this axis operates in pathological angiogenesis (tumors) was not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Phagocyte-intrinsic C5 production was identified as a key substrate source for local C5a generation during systemic candidiasis, with C5a–C5aR1 promoting macrophage survival via ERK/AKT/mTOR, establishing that tissue-autonomous complement production can be functionally dominant over circulating hepatic C5.\",\n      \"evidence\": \"C5ar1 KO mice in systemic candidiasis, macrophage survival assays with ERK/AKT pathway dissection, phagocyte C5 expression, patient correlation data\",\n      \"pmids\": [\"37220746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether phagocyte-intrinsic C5 is processed by classical convertases or alternative proteases locally was not resolved\", \"Relative contribution of local vs. circulating C5 in other infection models remains undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the atomic structure of C5 bound to a physiological C5 convertase, the precise conformational priming event enabling C5 cleavage, the molecular mechanism of C5aR2-mediated transcytosis, and the identity of phagocyte and cancer cell serine proteases that cleave C5 independently of convertases.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of C5 engaged with a C5 convertase exists\", \"Priming conformational change in C5 is inferred but not structurally captured\", \"C5aR2 transcytosis machinery not defined\", \"Phagocyte serine protease identity for non-convertase C5 cleavage unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 7, 8, 12, 24]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 6, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 14, 15, 16, 24]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 19, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 6, 10, 11, 18, 20, 21, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 9, 13, 19, 31, 34]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 13, 29]}\n    ],\n    \"complexes\": [\n      \"C5b-9 (membrane attack complex)\",\n      \"C5b-7\",\n      \"C5 convertase (C3bBbC3b or C4b2aC3b)\"\n    ],\n    \"partners\": [\n      \"C5AR1\",\n      \"C5AR2\",\n      \"C3B\",\n      \"C6\",\n      \"C7\",\n      \"TAFI\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Complement C5 is a central effector of innate immunity whose proteolytic cleavage generates two functionally distinct arms of the terminal complement pathway: the anaphylatoxin C5a and the MAC-initiating fragment C5b. C5 is cleaved by C5 convertases whose specificity is allosterically switched from C3 to C5 by increasing C3b surface density (>1000-fold Km shift), and also by non-complement serine proteases from activated phagocytes and cancer cells [PMID:12440962, PMID:12414531, PMID:25050844]. C5a signals through the Gi-coupled receptor C5aR1 (activating Ras/Raf/MEK/ERK and PI3K/Akt cascades) to drive neutrophil chemotaxis, mast cell migration, inflammasome priming, Fcγ receptor rebalancing, and platelet CXCL4 release, while C5aR2 modulates this signaling as both an endothelial transcytosis receptor delivering C5a into the vascular lumen and a negative regulator of C5aR1 via β-arrestin interaction [PMID:8090790, PMID:31076525, PMID:24179165]. C5b sequentially recruits C6 and C7 through its α′-chain cysteine-rich domains to form membrane-inserted MAC (C5b-9), which at sublytic concentrations activates ERK, PI3K/Akt, and cell-cycle entry independently of C5a signaling [PMID:1387399, PMID:15855657, PMID:11414362].\",\n  \"teleology\": [\n    {\n      \"year\": 1969,\n      \"claim\": \"Identification that C5 cleavage generates a potent leukocyte chemoattractant (C5a) established the first effector function of C5 beyond hemolysis and linked complement activation to cellular immune recruitment.\",\n      \"evidence\": \"In vitro chemotaxis assay with C5-derived fractions from human serum\",\n      \"pmids\": [\"5765461\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C5a structure unknown\", \"receptor identity unknown\", \"mechanism of C5 cleavage specificity unresolved\"]\n    },\n    {\n      \"year\": 1978,\n      \"claim\": \"Determination of the complete 74-residue primary structure of C5a, including three disulfide bonds and C-terminal Arg74 as critical for chemotactic potency, provided the first molecular framework for C5a pharmacophore studies.\",\n      \"evidence\": \"Protein sequencing, carbohydrate analysis, and functional chemotaxis assays of purified human C5a\",\n      \"pmids\": [\"690134\", \"342601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure undetermined\", \"receptor binding residues beyond Arg74 unknown\"]\n    },\n    {\n      \"year\": 1985,\n      \"claim\": \"Identification of the C5a receptor on neutrophils (~40 kDa binding moiety) by affinity cross-linking demonstrated a specific, saturable receptor distinct from other chemoattractant receptors, and NMR studies confirmed the predicted four-helix bundle core of C5a.\",\n      \"evidence\": \"125I-C5a affinity cross-linking with SDS-PAGE on human PMN; 3D heteronuclear NMR of 15N-labeled recombinant C5a\",\n      \"pmids\": [\"3997862\", \"2730871\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor primary sequence unknown\", \"G-protein coupling mechanism uncharacterized\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Reconstitution of C5b-6/C5b-7 membrane insertion with defined lipid vesicles revealed that C6 and C7 bind the C5b α′-chain and that negatively charged phospholipids are required for initial membrane association, defining the assembly pathway of the MAC.\",\n      \"evidence\": \"Lipid vesicle binding assays, bimolecular kinetics, and activation energy measurements with purified complement components\",\n      \"pmids\": [\"3801440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full MAC (C5b-9) assembly and pore structure unresolved\", \"membrane insertion mechanism of C8/C9 not addressed\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Cloning of C5aR revealed it as a seven-transmembrane GPCR, immediately explaining its Gi-dependent signaling properties and enabling targeted genetic and pharmacological studies.\",\n      \"evidence\": \"cDNA cloning from U937/HL-60 cells, heterologous expression in COS-7 cells with radioligand binding confirmation\",\n      \"pmids\": [\"1847994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascades not yet mapped\", \"second C5a receptor (C5L2/C5aR2) unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Systematic mutagenesis of C5a defined a two-domain pharmacophore (10 charged core residues + C-terminal Arg74, with Lys19/20 critical), while C5aR signaling was mapped to Gi-coupled Ras/Raf/MEK/ERK and PKC-dependent pathways, connecting ligand structure to intracellular signaling architecture.\",\n      \"evidence\": \"Site-directed mutagenesis with Ca2+ mobilization and receptor binding; kinase activity assays with pertussis toxin and PKC modulators in neutrophils\",\n      \"pmids\": [\"7987211\", \"8112341\", \"8090790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of C5a-C5aR interaction at atomic resolution not yet available\", \"receptor phosphorylation/desensitization cycle incomplete\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Discovery that C5aR undergoes GRK-mediated phosphorylation (Gi-independent) and requires PP1/PP2A-dependent dephosphorylation for recycling/resensitization defined the regulatory cycle controlling C5a responsiveness.\",\n      \"evidence\": \"32P-phosphorylation, pertussis toxin, okadaic acid treatment, and receptor trafficking kinetics in differentiated HL-60 cells\",\n      \"pmids\": [\"7706744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific GRK isoform identity unresolved\", \"phosphorylation sites on C5aR not mapped\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of C5aR N-terminal tyrosine sulfation (Tyr11, Tyr14) as essential for C5a docking, combined with the finding that sublytic MAC activates ERK/PI3K/Akt and cell-cycle entry, established two-site receptor engagement and separated the signaling roles of C5a and C5b-9.\",\n      \"evidence\": \"35S-sulfate labeling and mutagenesis of C5aR with functional assays; ERK/Akt kinase assays and cell-cycle analysis after sublytic MAC treatment\",\n      \"pmids\": [\"11342590\", \"11414362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of C5a–C5aR complex not yet solved\", \"MAC signaling receptor identity unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"C5 convertase specificity was quantitatively explained by C3b surface density (>1000-fold Km shift), while phagocyte-derived serine proteases were shown to generate C5a independently of complement convertases, revealing parallel activation pathways for C5.\",\n      \"evidence\": \"Km determination for reconstituted convertases at varying C3b densities; incubation of activated phagocytes with C5 plus serine protease inhibitor panels\",\n      \"pmids\": [\"12440962\", \"12414531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of phagocyte serine protease not determined\", \"structural basis of C3b density-dependent allosteric switch unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery that C5L2/C5aR2 binds C5a with high affinity but is obligately G-protein-uncoupled (DRY→DLC mutation), combined with genetic evidence that C5a/C3a drive liver regeneration via NF-κB/STAT-3, expanded C5 biology beyond immunity into regeneration and defined a second, non-signaling receptor.\",\n      \"evidence\": \"Pharmacological characterization of C5L2 (radioligand binding, cAMP, Ca2+, MAPK); complement-deficient mice with partial hepatectomy and C3a/C5a reconstitution\",\n      \"pmids\": [\"12899627\", \"12975457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C5L2 in vivo function unclear\", \"mechanism of C5a-driven hepatocyte proliferation beyond cytokine induction not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic mapping of C5 (Hc locus) as the causal gene for hepatic fibrosis susceptibility, validated by transgenesis and C5aR antagonist treatment, established C5a-C5aR as a therapeutic target in fibrotic disease.\",\n      \"evidence\": \"Congenic mice, BAC transgenesis, C5aR small-molecule antagonist in vivo, human hepatitis C genetic association\",\n      \"pmids\": [\"15995705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fibrogenic cell type responding to C5a not definitively identified\", \"mechanism of C5a-driven stellate cell activation unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"C5L2/C5aR2 was shown to have non-redundant pro-inflammatory roles in vivo (facilitating C5a signaling, mediating HMGB1 release in sepsis), resolving the initial characterization as merely a decoy receptor.\",\n      \"evidence\": \"C5L2-KO mice in LPS sepsis, OVA airway inflammation, and CLP sepsis models; HMGB1 ELISA; dual C5aR1/C5aR2 blockade\",\n      \"pmids\": [\"17322907\", \"18454156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which C5aR2 signals without G-protein coupling not defined\", \"cell-type-specific roles of C5aR2 (macrophage vs. endothelium) not delineated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery of the C5 p.Arg885His variant that retains hemolytic function but abolishes eculizumab binding explained clinical resistance in PNH patients, demonstrating that therapeutic anti-C5 antibodies target a defined epitope distinct from the convertase cleavage or MAC-assembly sites.\",\n      \"evidence\": \"Gene sequencing, hemolysis assays with mutant C5, eculizumab and N19-8 binding assays in PNH patient-derived samples\",\n      \"pmids\": [\"24521109\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise structural basis of eculizumab–C5 interaction not yet resolved at atomic level at this time\", \"frequency of resistance variants in non-Asian populations unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Crystal structures of C5 bound to three structurally distinct inhibitors (tick OmCI-class proteins, eculizumab Fab) at non-overlapping sites—all blocking convertase activation—established that C5 requires a conformational priming event for cleavage, not merely enzyme access to the scissile bond.\",\n      \"evidence\": \"X-ray crystallography of C5–inhibitor complexes with competitive convertase inhibition assays\",\n      \"pmids\": [\"27018802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of the conformational priming event uncharacterized\", \"C5 convertase–C5 complex structure not solved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Crystal structures of C5aR1 with orthosteric (PMX53) and allosteric (avacopan) antagonists revealed two druggable binding sites and a novel helix-8 conformation, providing the structural basis for rational C5aR1 drug design.\",\n      \"evidence\": \"X-ray crystallography of C5aR1 ternary complexes, computational docking, cell-based signaling assays\",\n      \"pmids\": [\"29867214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state C5aR1 structure with C5a not available\", \"structural basis of biased agonism/antagonism at C5aR1 unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"C5aR2 was revealed to function as a transcytosis receptor on endothelial cells, transporting C5a from tissue to vascular lumen to initiate C5aR1-mediated neutrophil arrest, while simultaneously acting as a negative regulator of C5aR1 via physical interaction with β-arrestin—resolving the paradox of C5aR2's dual pro- and anti-inflammatory roles.\",\n      \"evidence\": \"Intravital microscopy with C5aR2-KO mice; co-immunoprecipitation of C5aR2–C5aR1–β-arrestin; MPO-ANCA GN model with receptor KOs\",\n      \"pmids\": [\"31076525\", \"24179165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of C5aR2 transcytosis mechanism unresolved\", \"endothelial vs. leukocyte C5aR2 contributions not fully dissected\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Phagocyte-intrinsic C5 production (not only liver-derived C5) was shown to be a critical substrate source for C5a-C5aR1 antifungal defense, with C5aR1 signaling promoting phagocyte survival via ERK/Akt/mTOR-dependent metabolic reprogramming.\",\n      \"evidence\": \"C5ar1-KO mice with systemic candidiasis, RNA-seq, metabolomics, mTOR pathway inhibition, phagocyte-specific C5 expression analysis\",\n      \"pmids\": [\"37220746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease responsible for phagocyte-autonomous C5 cleavage not identified\", \"relative contribution of local vs. hepatic C5 in other infectious or inflammatory contexts unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of the C5 convertase–C5 complex (and the nature of the conformational priming event required for cleavage), the identity of the phagocyte serine protease that cleaves C5, the active-state structure of C5aR1 bound to C5a, and the receptor/mechanism by which sublytic MAC activates intracellular signaling.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"C5 convertase–C5 complex structure not solved\", \"Phagocyte C5-cleaving protease not identified\", \"Active-state C5a–C5aR1 structure unavailable\", \"MAC signaling receptor unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 7, 14, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [24, 50]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 3, 7, 24, 26]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 11, 19, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 13, 16, 18, 28, 30, 40, 47, 49]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 20, 23, 28, 34, 46]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [3, 26]}\n    ],\n    \"complexes\": [\n      \"MAC (C5b-9)\",\n      \"C5b-6\",\n      \"C5b-7\"\n    ],\n    \"partners\": [\n      \"C5AR1\",\n      \"C5AR2\",\n      \"C6\",\n      \"C7\",\n      \"C3B\",\n      \"CFHR1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}